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Available online 11 June 2016Acetylation is one of the major post-translational protein modiﬁcations in the cell, with manifold effects on the
protein level as well as on the metabolome level. The acetyl group, donated by the metabolite acetyl-
coenzyme A, can be co- or post-translationally attached to either the α-amino group of the N-terminus of
proteins or to the ε-amino group of lysine residues. These reactions are catalyzed by various N-terminal and
lysine acetyltransferases. In case of lysine acetylation, the reaction is enzymatically reversible via tightly regulated
and metabolism-dependent mechanisms. The interplay between acetylation and deacetylation is crucial for
many important cellular processes. In recent years, our understanding of protein acetylation has increased signif-
icantly by global proteomics analyses and in depth functional studies. This review gives a general overview of
protein acetylation and the respective acetyltransferases, and focuses on the regulation of metabolic processes
and physiological consequences that come along with protein acetylation.










Protein acetylation is one of the major post-translational modiﬁ-
cations (PTMs) in eukaryotes, in which the acetyl group from acetyl
coenzyme A (Ac-CoA) is transferred to a speciﬁc site on a polypep-
tide chain. Alongside acetylation, phosphorylation, methylation,
SUMOylation, and ubiquitination have been studied intensively.
These PTMs introduce new functional groups to proteins, thereby ex-
tending the repertoire of the standard amino acid residues. Most
PTMs are important pillars of cell signaling and enable the cell to
react speciﬁcally and rapidly to internal and external perturbations
[1]. Other PTMs occur when the cell encounters speciﬁc environmen-
tal stress conditions as is the case during oxidative stress, e.g. carbon-
ylation and oxidation [2]. With new techniques emerging, especially
in the mass spectrometry ﬁeld, hundreds of different PTMs were
identiﬁed [3–5]. Protein acetylation normally occurs in two distinct
forms, which combined constitute the cell-wide acetylome. In
humans, 80–90% of all proteins become co-translationally acetylated
at their Nα-termini of the nascent polypeptide chains (Fig. 1A) [6–8].
In recent years, it was shown that this N-terminal (Nt) modiﬁcationBiology, University of Bergen,
.
. This is an open access article underalso occurs post-translationally for several proteins, demonstrating
that Nt-acetylation is part of a more complex system [8–11]. These
reactions are catalyzed by Nt-acetyltransferases (NATs) [12]. The
other common type of protein acetylation pertains to the ε-amino
group of lysines (Fig. 1B). Acetylated lysine residues were ﬁrst
discovered in histones regulating gene transcription, which is the
reason why the enzymes catalyzing lysine (K) acetylation were
termed histone acetyltransferases (HATs) [13]. Nevertheless, lysine
acetylation is not exclusively limited to histone proteins [14], and
the enzymes have been renamed lysine (K) acetyltransferases
(KATs) [15]. In contrast to Nt-acetylation, which is considered irre-
versible, the acetylation status of a lysine is reversible and tightly
regulated. Several families of lysine deacetylases (KDACs) are
counteracting KATs. KATs and KDACs developed a well-balanced
and complex interaction inmany cell functions. Due to the consump-
tion of Ac-CoA during acetylation and NAD+ during deacetylation by
speciﬁc KDACs (Fig. 1C), acetylation interferes with metabolic pro-
cesses and energy homeostasis. Consequently, malfunctioning
acetylation machinery can lead to severe diseases such as cancer,
neurodegenerative diseases and cardiovascular disorders [16–22].
The present knowledge in the ﬁeld teaches us many facts about the
acetyltransferases themselves, the reaction they are catalyzing, and
the molecular consequences for their substrates. Nevertheless, the
understanding of the physiological consequences acetylation pro-
vokes, or the overall interplay and regulation of the acetylome itself,
still remain elusive.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic overviewof acetylation anddeacetylation. A) Enzymatic transfer of an acetyl group fromAc-CoA to theN-terminal amino group of a polypeptide, catalyzed byN-terminal
acetyltransferases (NATs). The reaction is considered to be irreversible. B) Reversible acetylation of the ε-amino group of a lysine residue by lysine acetyltransferases (KATs). The
deacetylation of lysine residues is catalyzed by Lysine deacetylases (KDACs) and C) is NAD+-dependent in case of sirtuins. NAD+, nicotinamide adenine dinucletide; NAM, nicotinamide.
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2.1. N-terminal acetylation in general
2.1.1. Abundancy from Escherichia coli to Arabidopsis thaliana
Nt-acetylation is an abundant co- and post-translational modiﬁca-
tion,which is conserved in all branches of life. The frequency of acetylat-
ed proteins increases with the complexity of the organism [7,23,24]. In
bacteria and archaea Nt-acetylation was considered to be a rare event,
and it seems that this modiﬁcation does not exist in all species [23]. In
Escherichia coli only 5 proteins have long been known,mainly ribosomal
subunits, to carry an acetyl group at their N-termini. However, a recent
MS-based proteome-wide study in E. coli, analyzing PTMs under differ-
ent growth conditions, identiﬁed 31 proteins being Nt-acetylated [25].
Noteworthy, these acetylation reactions all occur post-translationally
[26,27]. In addition, new Nt-acetylated proteins have been identiﬁed
in different bacterial species showing that Nt-acetylation occurs more
frequently than ﬁrst expected, actually playing important roles in
these organisms [28–30]. In Drosophila melanogaster, 861 out of 1226
distinct N-termini identiﬁed have been found fully Nt-acetylated [31].
In yeast, the percentage of fully or partially Nt-acetylated proteins is ap-
proximately 50–70% (from 614 identiﬁed endogenous yeast proteins)
[7]. Compared to that, the human Nt-acetylome consists of around
80–90% of the soluble protein fraction [7,24]. To complete the list, it
should be mentioned that the abundancy of Nt-acetylation in the
plant model organism Arabidopsis thaliana is around 72% [32].
2.1.2. The reaction catalyzed by NATs
NATs transfer an acetyl moiety from Ac-CoA to the positively
charged free α-amino group of a newly synthesized polypeptide chain
(Fig. 1A). The attached acetyl group neutralizes this positive charge
and normally blocks theN-terminus from furthermodiﬁcations. Depen-
dent on the NAT, the acetyl group is transferred to the non-cleavedinitial methionine residue (iMet) of the nascent polypeptide chain or
the reaction occurs after the excision of the iMet by ribosomal-bound
methionine aminopeptidases (MetAPs) [33–36]. The N-terminus is
also subject to other PTMs, such as propionylation or arginylation
[37–39]. Not all potential NAT substrates are completely Nt-acetylated.
Partial Nt-acetylation is common, consequently a protein can exist in
its unacetylated and its acetylated form simultaneously in the cell
[12]. In recent years, structural studies delivered insights into the cata-
lytic mechanism of NATs. In addition, several molecular consequences
for proteins, becoming Nt-acetylated, were revealed by selected exam-
ples. Nevertheless, the connections between Nt-acetylation and physio-
logical processes have not been fully elucidated. This also includes the
rising numbers of cellular malfunctions and diseases that arise by NAT
deﬁciency and mutations, respectively, and demonstrates the
importance of closing these knowledge gaps.
2.2. The N-terminal acetyltransferases (NATs)
2.2.1. The subunit composition of the NATs
NATs belong to the GCN5 (general control non-derepressible 5)-re-
lated acetyltransferase (GNAT) superfamily, which also include some of
the well-studied KATs. The enzymes of the GNAT family share con-
served sequence motifs including the recognizable Ac-CoA binding
motif Q/RxxGxG/A [40,41]. NATs are mono- or multisubunit enzymes
consisting of a catalytic subunit and up to two auxiliary subunits
(Fig. 2). The major auxiliary subunit modulates the activity and
substrate speciﬁcity of the catalytic subunit [42]. Further, the auxiliary
subunits are considered to mediate, in co-translational reactions, the
complex binding to the ribosome as well as to the nascent polypeptide
via several tetratricopeptide repeatmotifs [43–45]. To date, six different
NATs have been identiﬁed in mammals (NatA-NatF), whereas in yeast
only ﬁve NATs exist (NatA-NatE) [12]. Noteworthy, in E. coli the only
acetyltransferases that have been identiﬁed so far are RimI, RimJ, and
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[26,46–48]. The main NAT complexes in eukaryotes, NatA, NatB, and
NatC, are combined responsible for approximately 80% of all Nt-
acetylation reactions in human cells [12,49]. NatA is composed of the
catalytic subunit Naa10 (Ard1) and the auxiliary subunit Naa15 (Nat1)
[50,51]. Naa50 co-exists in this complex [43,52,53], but possesses its
own catalytic activity and is thus termed NatE [10,35,54]. Naa10 is
also able toNt-acetylate independently of Naa15 [10]. NatB is composed
of the catalytic subunit Naa20 (Nat3) and the auxiliary subunit Naa25
(Mdm20) [55,56]. The catalytic subunit of NatC is Naa30 (Mak3) [57],
which is associated with the two auxiliary subunits Naa35 (Mak10)
and Naa38 (Mak31) [58,59]. NatD, NatE and NatF are monosubunit en-
zymes, composed of only their catalytic subunits Naa40, Naa50, and
Naa60, respectively [8,10,24,54,60,61]. Interestingly, in contrast to the
complexes NatA to NatE, which are all localized in the cytosol binding
to ribosomes, NatF is associated with the Golgi apparatus [8]. Recently,
a new NATwas identiﬁed in A. thaliana, named AtNAA70making an ex-
ception in the NAT ﬁeld due to its unique localization and activity in
chloroplasts [62]. It is likely that in the upcoming years more NATs
will be identiﬁed and characterized.
2.2.2. NATs vary in their substrate speciﬁcities
The various NATs differ not only in subunit composition, but also in
their substrate speciﬁcity, which is determined in general by the ﬁrst
two amino acid residues (Fig. 2) [63]. NatA acetylates S-, A-, T-, V-, G-,
and C- N-termini after iMet excision [7,64]. Naa10 is also active in the
absence of Naa15, post-translationally acetylating acidic N-termini [10,
42]. NatB acetylates proteins with a retained iMet followed by an acidic
or hydrophilic amino acid residue (e.g. D, N, E, Q) [56,64,65]. NatD has
only two known substrates, the histones H2A and H4 [60,61]. NatC,
NatE, and NatF have overlapping substrate speciﬁcities, potentially
acetylating proteins starting with the iMet followed by amphipathic
and hydrophobic amino acid residues (e.g. K, M, V, A, L, I, F, and Y) [8,
10,24,54,57,59]. AtNaa70 prefers chloroplast N-termini beginning with
M, A, S, and T [62]. N-termini starting with a proline are never found
to be Nt-acetylated [7,31].
2.3. Molecular consequences of being Nt-acetylated
The consequences of being Nt-acetylated for a protein are manifold.
Nt-acetylation determines the subcellular localization for certain pro-
teins. Arl3 andGrh1are twoGolgi-associated proteins,which are unable
to associate with the Golgi apparatus whenmissing the Nt-acetyl group
(Fig. 3A) [66–68]. Another study hypothesizes that Nt-acetylation re-
strains proteins in the cytosol and inhibits a post-translational translo-
cation migration to the endoplasmic reticulum (ER) and the secretory
pathway (Fig. 3B) [69]. Acetylation alters the properties of the N-
terminus, and thus protein-protein interactions apparently become
modulated. It was shown for several proteins that the afﬁnity to their
binding partners increased after being Nt-acetylated. The E2 ubiquitin-
conjugating enzyme Ubc12 undergoes Nt-acetylation by NatC enabling
an increased afﬁnity towards its interaction partner, the E3 ubiquitin li-
gase Dcn1 (Fig. 3C) [70]. This Nt-acetylation-dependent interactionwas
found to be a conserved mechanism for the complete mammalian
NEDD8 ligase family [71]. It was shown that Nt-acetylation by NatB
plays an important role in tropomyosin-actin complex formation.
When tropomyosin is Nt-acetylated the end-to-end bonds are stronger.
Concomitantly, this increases actin binding and facilitates the regulation
of speciﬁc myosin motor classes [55,72]. A recent publication showedFig. 2. The human N-terminal acetyltransferase machinery. The human NAT machinery consist
one catalytic subunit (blue), and one or several auxiliary subunits. NatD-F are mono-subunit
termini containing iMet followed by a small amino acid such as S-, A-, V-, G-, C-, T- and P-,
typically Nt-acetylated by NatA. NatD Nt-acetylates speciﬁcally the S-G- N-terminus of the his
are Nt-acetylated by NatE or NatF. NatB Nt-acetylates M-D-, M-E-, M-N- and M-Q, however, a
M-Q- is also Nt-acetylated by NatF. NatC, NatE and F have overlapping substrate proﬁles and d
(M-W-, M-L-, M-F- and M-I-). NatE and NatF also Nt-acetylate M-M-, M-Y-, M-K-, M-H- and Mthat Nt-acetylation is also crucial for protein folding by structurally sta-
bilizing ﬂexible N-termini. In the absence of NatA in yeast, misfolded
and aggregated proteins accumulate and result in an increased chaper-
one expression [73]. Themost prominent effect of Nt-acetylation relates
to protein stability. Nevertheless, this topic is controversial. Several ex-
amples exist showing that Nt-acetylation increases the stability and
half-life of proteins such as tuberous sclerosis complex 2 (TSC2),
which is involved in tumorigenic processes [74], and THO complex sub-
unit seven homolog (THOC7) [19]. Other recent studies demonstrate
that Nt-acetylated N-termini may act as proteasomal degradation
signals, decreasing protein half-life and being part of the N-end rule
pathway [75,76]. Certain acetylated N-termini are recognized by specif-
ic E3 ubiquitin ligases thereby opening a new branch of the N-end rule
pathway, the Ac/N-end rule. This degradation pathway may in some
cases regulate the stoichiometry of protein subunits of a complex
when complex formation shields the N-terminal degradation signal
(Fig. 3D) [76,77]. Here are only a few examples listed of the manifold
effects Nt-acetylation has on proteins, and following studies will give
further insights and certainly decipher new impacts and regulation
mechanisms of Nt-acetylated proteins.
2.4. Putative cellular and physiological roles of NATs
2.4.1. NATs are essential for normal development
Naa10 is conserved from yeast to humans and its critical role in
normal development is demonstrated in humans as well as zebraﬁsh
and different invertebrates. In a recent Danio rerio study, naa10
morpholino-mediated knockdown resulted in severe phenotypes with
increased lethality, developmental abnormalities and growth retarda-
tion, which emphasizes the importance of a normal Naa10 expression
level for viability and early development of zebraﬁsh [78]. Studies
from other organisms demonstrate that loss of the Naa10 homolog re-
sults in lethality for Drosophila melanogaster [79], Trypanosoma brucei
[80] as well as Caenorhabditis elegans [81]. In yeast, NatA was shown
as non-essential. However, naa10Δ or naa15Δ deletion strains have
defects in mating, sporulation and entry into stationary phase as well
as increased sensitivity towards temperature, salt and drugs [7,50,82].
A highly regulatedNAT expression is essential for human life, as demon-
strated by different diseases (Section 2.5), NAT mutations (Section 2.6)
and cancer studies (Section 2.7). The NATs' manifold functions in
mammalian/human development and cellular regulation are further
described in the following sections.
2.4.2. NAT involvement in bone and blood vessel development
Yoon et al. demonstrate Naa10 involvement in osteoblast differenti-
ation and early phases of bone formation by control and ﬁne-tuning of
the Runt-related transcription factor 2 (Runx2) signaling [83]. Naa10 in-
teracts with Runx2 and appears to acetylate K225 in the Runx2-domain.
This disrupts Runx2/CBFβ interaction and thereby inhibits the
transcriptional activity of Runx2. Runx2 on the other hand, stabilizes
Naa10 in osteoblasts during bone morphogenic protein 2 (BMP-2)-in-
duced differentiation, which in turn inhibits Runx2.
Naa15may also play an important role in osteogenesis due to its pre-
dicted function as a nuclear transcriptional regulator. One study indi-
cates that Naa15, Ku70 and Ku80 bind the osteocalcin promoter and
activate osteocalcin expression synergistically with Runx2 [84]. Howev-
er, follow up studies are necessary to conﬁrm these observations. In
contrary to Naa10 knockdown, which increases the stimulatory effects
of BMP2 on osteoblastgenesis and enhances differentiation ofs of six different NAT complexes, NatA-F. NatA-C are multi-subunit enzymes consisting of
enzymes, with the exception of NatE/Naa50 that also can exist in complex with NatA. N-
often undergo iMet cleavage performed by MetAP. With the exception of P-, these are
tones H2A and H4. However, if iMet is retained in the S-, A-, V-, G-, T- N-terminus, these
ctins are further processed by actin aminopeptidase (ActAP) and Nt-acetylated by Naa10.
emonstrate a redundancy between these NATs, Nt-acetylating hydrophobic amino acids
-R-, but the latter two might also be substrates for other NATs.
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the Naa10-dependent lysine acetylation of Runx2 [83].
Naa15 is also suggested to be involved in blood vessel development
as its expression is tightly regulated during formation andmaturation of
a subset of blood vessels and hematopoietic cells. The distribution and
regulated expression level implicate Naa15 to play a unique role in
both myelopoiesis and heart development as well as other tissues
[85]. Furthermore, knockdown of NAA15 leads to increased albumin
permeability and demonstrate Naa15 as an important regulator of vas-
cular permeability, in particular the retinal endothelial permeability of
albumin [86,87]. Src and the Src substrate, cortactin, are essential factors
in the signaling pathwaysmediating endothelial cell permeability. More
speciﬁcally, cortactin regulates actin assembly, cytoskeletal remodeling
and the endothelial barrier integrity and exists in complex with Naa15.
Importantly,NAA15 knockdown resulted in increased levels of activated
Src family kinases as Src, Fyn and Lyn, including increased level of phos-
phorylated cortactin. This further explains the Naa15 regulation of albu-
min to go through the Src/cortactin signaling pathway, and thereby
maintaining the homeostasis and vascular barrier function [88]. Loss
of Naa15 expression was also reported as a contributing factor to the
development of age-related retinopathy [87]. A recent study describes
Nt-acetylation of phosducin-like 3 (PDCL3), a chaperone protein
inhibiting proteasome degradation of vascular endothelial growth fac-
tor receptor (VEGFR)-2, both essential for angiogenesis [89]. Nt-
acetylation by NatB was shown to regulate the stability of PDCL3 and
as a consequence the VEGFR-2 expression.
These studies further conﬁrm Naa10 and Naa15 to play important
roles as regulators of bone differentiation, angiogenesis and retinal
vascular permeability.
2.4.3. Nt-acetylation regulates blood pressure
A study by Hwang, Varshavsky and colleagues links Nt-acetylation-
dependent andN-end rule-mediated degradation to blood pressure reg-
ulation [90]. Rgs2, a key G-protein regulator, lowers blood pressure in a
complex process decreasing signaling through Gαq. This protein is in-
volved in regulation of stress responses, hormones, translation, Ca2+
channels, cardiac rhythms and cardiovascular homeostasis [91–98].
Human patients displaying a decreased Rgs2 signaling, due to the
presence of Rgs2 mutants (ML-Rgs2 and MR-Rgs2), are hypertensive
compared to humans expressing wild-type Rgs2 (MQ-Rgs2). Interest-
ingly, different N-end rule degradation pathways target the mutant
Rgs proteins [90]. Wild-type Rgs2 and ML-Rgs2 were degraded by the
Ac/N-end rule pathway, recognizing Nt-acetylated proteins, acetylated
by NatB and NatC, respectively. The mutant Rgs2 protein (ML-Rgs2), a
relatively short-lived protein, was additionally targeted by the Arg/N-
end rule degradation pathway, recognizing free N-terminal residues.
This example represents a regulation mechanism mediated by
Nt-acetylation of proteins with an impact at the molecular, cellular
and physiological level [99].
2.4.4. NAT regulation of proteasome localization
Degradation of proteins in response to speciﬁc degradation signals
as consequence of their localization, stoichiometry or misfolding, is an
important aspect of a healthy cell. The proteasome localizes to nucleus
and cytoplasm as well as to cytoplasmic proteasome storage granules
(PSGs). The mechanism underlying the different proteasome localiza-
tions in cells involves selective Nt-acetylation as Nt-acetylation is asso-
ciatedwith bothproteasomedistribution and PSG formation [100]. NatC
has a speciﬁc role in nuclear enrichment of the proteasome during star-
vation, a phenotype correlated with replicative age. However, loss of
NatC has no effect on PSG formation. In contrary, NatB knockouts dem-
onstrate lack of PSG formation, indicating that NatB plays a speciﬁc role
here. As with NatC–deﬁcient cells, NatB-deﬁcient cells display a nuclear
enrichment of the proteasome. NatA deﬁciency on the other hand did
not alter the proteasome distribution.While NatA andNatB control gen-
eral cell ﬁtness during starvation, NatC has a selective effect on theﬁtness of old cells only. This demonstrates aging as a process also affect-
ed by Nt-acetylation, at least in budding yeast.
2.4.5. NAT involvement in organelle structure and function
NatA-mediated Nt-acetylation is also linked to selective mitochondri-
al degradation, in particular to induction and regulation of the
mitochondria-anchored receptor Atg32, a protein essential formitophagy
and formation of mitochondria-speciﬁc autosomes [101]. In addition,
NatA-mediated Nt-acetylation of Brx1 is necessary for proper ribosomal
biogenesis in conjunctionwith Ebp2 [102]. NatC Nt-acetylation of several
mitochondrial proteins; Kdg1, Fum1 and Mrp has been suggested [103],
aswell asNt-acetylation of the L-A gag protein, necessary for viral particle
assembly and L-A viral propagation [57]. NatD-mediated Nt-acetylation
of histoneH4 regulate argininemethylation and thereby silence ribosom-
al DNA [104]. Both NatE and NatF depleted cells display chromosomal
segregation defects [24,52,105]. Studies by Pimenta-Marques et al.
further demonstrate Naa50 requirement for normal sister chromatid
cohesion and chromosome condensation [106]. NatF is membrane-
associated with the Golgi complex and essential for regulation of organ-
elle structure and function, in particular for maintaining Golgi structural
integrity [8]. The exact mechanism remains unknown, but may depend
on both NatF Nt-acetylation of transmembrane proteins involved in the
maintenance of Golgi as well as direct protein interaction and regulation.
2.4.6. Nt-acetylation in hormone regulation
Although Nt-acetylation occursmainly co-translationally, it also takes
place at internal sites after speciﬁc proteolytic processing of the translat-
ed protein and has profound physiological regulatory effects. This is the
case for the peptide hormones α-melanocyte-stimulating hormone (α-
MSH) and β-endorphin (β-END), both derived from extensive enzymatic
cleavage of the precursor hormone proopiomelanocortin (POMC) and
expressed in the hypothalamus, pituitary gland as well as in skin cells
[107,108]. These two hormones play key roles in the regulation of a
variety of physiological processes, including appetite, metabolism, sexual
behavior, inﬂammation and pain sensation. Their biological activities are
oppositely modulated by Nt-acetylation; while Nt-acetylation increases
α-MSH stability and potency [109–111], this modiﬁcation reduces
β-END afﬁnity to opioid receptors and results in an inactive hormone
[112,113].
2.5. NATs and Nt-acetylation in neurodegenerative disease
Neurodegenerative diseases such asAlzheimer's disease, Parkinson's
disease and Lewy body dementia are characterized by formation of
pathogenic ﬁbrils composed of insoluble proteins in the brain. Dysfunc-
tional NATs and lack of Nt-acetylation are associated with several of
these neurodegenerative disorders. The Huntingtin (Htt)-interacting
protein K (HYPK) act as a chaperone and prevent aggregation of
polyglutamine Htt [114]. As shown in Fig. 2, HYPK exist in complex
with NatA, stabilizing HYPK's functions [115]. Arnesen and colleagues,
showed HYPK as essential for NatA-mediated Nt-acetylation. Interest-
ingly, knockdown studies ofHYPK,NAA10 orNAA15 further demonstrat-
ed increased aggregation of Htt. Htt is a typical NatA substrate and lack
of NatA Nt-acetylation as well as destabilization of HYPK result in in-
creased aggregation of Htt proteins, suggesting a direct link between
NatA and prevention of Huntington's disease [115]. Another study
links NatA activity to Alzheimer's disease [116]. Naa10 interacts with
the cytoplasmic domain of the β-amyloid precursor protein (APP), a
protein that is processed to the amyloid β-protein (Aβ), which is the
main component of amyloid plaques contributing to the development
of Alzheimer's. Co-expression of Naa15 suppresses Aβ-protein secre-
tion, indicating that the NatA complex stabilizes APP and/or that the
Nt-acetylation reduces Aβ generation. Additionally, NatA regulates pro-
tein folding through the action of chaperones in yeast, thereby promot-
ing prion [PSI+] propagation and further demonstrates the contribution
of Nt-acetylation in amyloidogenesis [73]. In Parkinson's,α-synuclein is
Fig. 3.Molecular effects of Nt-acetylation. Nt-acetylation has various putative roles depending on themodiﬁed protein. A) The small GTPase, Arl3p, needs Nt-acetylation for correct subcellular
localization to the Golgi as themodiﬁcation functions as an N-terminal membrane anchor. B) Nt-acetylation can retain proteins in cytosol and prevent their post-translational translocation to
ER. C) Nt-acetylation enables protein-protein interaction as shown by the E3 ligase Ubc12, which is interacting with the E2 ubiquitin-conjugating enzyme Dcn1. The hydrophobic pocket of
Dcn1 binds the Nt-acetylated methionine of Ubc12 and activates the neddylation complex. D) Nt-acetylation controls protein quality and lifetime, and regulates the protein stoichiometry
by the N-end rule pathway. Nt-acetylation of protein P1 facilitates proper protein folding and thereafter stabilizes P1 in a long-lived protein complex with protein P2. When unshielded, an
acetylated N-terminus can function as an Ac/N-degron, which recognized by E3 ligases. Thus, the Nt-acetylated protein is targeted for ubiquitination and following proteasomal degradation.
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involved in lipid binding, synaptic vesicle trafﬁcking aswell as neuronal
cell survival, but the exactmechanism remains unknown [118]. Howev-
er, NatB-mediated Nt-acetylation of α-synuclein plays an essential role
in folding of the stable α-helical tetramer, and makes the protein resis-
tant for amyloid aggregation [119,120]. Nt-acetylation is a general
mechanism for stabilizingα-helical structures in both proteins and pep-
tides [121], and enhance both protein-protein and protein-membrane
interaction of α-synuclein [119,120]. More speciﬁcally, Nt-acetylation
mediates speciﬁcity and enhanced interaction between α-synuclein
and the neuronal ganglioside GM1. This promotes membrane binding
and stabilization of the helical formation of α-synuclein. Thus, Nt-
acetylation may have a protective function and potentially plays an im-
portant role in preventing early development of Parkinson's.
2.6. Human disorders caused by NAT mutations
The importance of functional NATs and the physiological roles of Nt-
acetylation have been further unraveled in the recently identiﬁed path-
ological conditions caused by amalfunctioningNATmachinery, demon-
strating NATs to be essential during early embryogenesis and their
important regulatory functions during tissue and organ development.
During the last ﬁve years, several mutations in the genes encoding
NatA subunits have been discovered and all patients with NAA10muta-
tions have some clinical features in common regardless of their syn-
drome. These include developmental delays (ranging from mild to
severe), hypotonia, scoliosis and recurrent infections. The X-linked le-
thal human genetic disorder Ogden syndrome, identiﬁed in 2011 and
affecting only male infants, is caused by a p. S37P mutation in exon 2
of theNAA10 gene. [22]. The syndrome is characterized by severe devel-
opmental delay, a unique combination of craniofacial anomalies, aged
appearance, hypotonia, cardiac arrhythmia followed by cardiomyopa-
thy, being lethal during infancy. Subsequent molecular studies found
Naa10 S37P cells to have both reduced complex formation with Naa15
and Naa50, and up to 80% reduced in vitro catalytic activity, explaining
the observed decrease in NatA and NatE-type substrate Nt-acetylation
[19]. The Naa10 S37P cells further showed a reduced cell proliferation
via perturbed Rb1-pathway and dysregulated cell contact inhibition
and migration. In yeast, the Naa10 S37P mutation displayed impaired
functionality in vivo. Yeast cells expressing the mutant human Naa10-
Naa15 complex displayed a reduced degree of Nt-acetylation of NatA
substrates as compared to yeast cells expressing the wildtype human
NatA complex [122]. Another exome sequence study identiﬁed a
NAA10missensemutation, p. R116W (exon 5), in an intellectual disabil-
ity syndrome [123]. Yet, another de novomissense variant in the NAA10
gene, p. V107F (exon 6), was identiﬁed in an unrelated girl with severe
global development delay [20]. Based on 3D homology modeling it was
suggested that Naa10 R116W has impaired catalytic activity, due to in-
terference with CoA binding. The V107F mutation was suggested to re-
duce Naa10 protein stability or enzymatic activity as the bulky side
chain did not ﬁt into the hydrophobic core of the protein. As in the
case with the S37P mutation, both R116W and V107F signiﬁcantly re-
duce the in vitro catalytic activity of Naa10. However, while R116W
showed a 15% reduction in catalytic activity, the V107F was almost cat-
alytically deadwith a 95% reduction but still showed amilder non-lethal
phenotype than the Ogden syndrome affected infants. Of notice, the girl
with this severe mutation was hemizygous and additionally had a WT
NAA10 allele. A skewed X-inactivation pattern was not identiﬁed.
Thevenon and colleagues report yet another de novomissensemutation
in NAA10, the c. 364A N T, p. F128I in a girl which share several clinical
features with the girl harboring the V107F mutation [124]. A recent
study presented two brothers with another novel NAA10missense var-
iant, p. Y43S (exon 3), causing an intellectual disability syndrome with
facial dysmorphic features, hypotonia, scoliosis and long QT due to
NAT impairment [125]. Saunier and colleagues identiﬁed three novel
Naa10 mutations; the R83C mutation was detected in a male andseven girls, while the F128L mutation and F128I was detected in a girl
each [126]. Both R83C and F128L demonstrated a 60–90% reduced cata-
lytic activity. While the F128L and F128I mutation were demonstrated
to interfere with the overall structure of Naa10 and destabilize the pro-
tein, the R83C mutation was shown to interfere with the Ac-CoA bind-
ing. Again moderate to severe developmental delay, intellectual
disability, microcephaly, skeletal, brain and organ anomalies were ob-
served among the affected individuals [126]. Another disease connected
to a dysfunctional Naa10 is Lenz microphthalmia syndrome (LMS),
characterized with congenital bilateral anophthalemia, postnatal
growth failure, hypotonia and skeletal anomalies, mild to severe intel-
lectual disability and delayed motor development, yet clinically distinct
and with a milder phenotype than observed for the Ogden syndrome
males [22]. The splice donor mutation (c.471 + 2T→ A) in intron 7 of
NAA10 results in alternative splicing, aberrant NAA10 transcripts and a
C-terminally truncated Naa10, but a maintained NAT catalytic domain
[127]. However, the mutation results in lack of wt Naa10 protein ex-
pression in addition to low expression of aberrant Naa10 transcripts, a
combination that most likely results in reduced Nt-acetylation of
NatA-type proteins essential for normal development. In fact, LMS ﬁbro-
blasts showed similar cell proliferative defects as the Naa10 S37P mu-
tated ﬁbroblasts. Exon 8 in NAA10 is conserved in mammals and
suggests that loss of exon 8 could be detrimental to its function. Further-
more, the C-terminal of Naa10 (part of exon 8) has been reported to be
required for interaction with TSC2, an inhibitor of the mTOR pathway
[74]. The truncated Naa10 cells demonstrate both loss of Naa10-TSC2
binding and reduced TCS protein levels, and thereby a perturbed
mTOR signaling. Interestingly, several genes involved in embryonic,
organ, tissue, skeletal andmuscular systemdevelopmentwere differen-
tially expressed in these splice donor mutated cells, in particular genes
associatedwith the retinoic acid andWnt signaling pathways, both nec-
essary for normal eye development [127].
One study suggests an association between common birth defects
and congenital heart disease and de novo putative frameshift mutations
in NAA15 [128]. These ﬁndings are relatively similar to the anomalies
found in patients with dysfunctional Naa10, suggesting that they may
be caused by lack of NatA-mediated Nt-acetylation.
It appears that only patients withmutations in theN-acetyl transfer-
ase domain with mutations in exon 2–6 (except from LMS patients),
have cardiac arrhythmias. Future studies of Naa10 inﬂuence on arrhyth-
mia genes either directly interaction or downstream signaling effects
are therefore necessary. The NAA10 knock-down/knock-out studies in
addition to the increasing number of Naa10 mutations found in differ-
ent human pathologies strengthens the notion that Naa10 and NatA
are involved in signaling pathways crucial for normal development.
However, the correlation between mutant NatA enzyme activity and
phenotype severity is more complex than ﬁrst anticipated. Viewing
the Naa10 interaction complexity it is reasonable to believe that
Naa10 mutants cause disease through several mechanisms and have
pleiotropic effects. Thus, in-depth functional studies, both at themolec-
ular and cellular level, are needed to understand the complex relation in
human developmental diseases and provide insight into the underlying
pathogenic mechanism.2.7. NAT-involvement in tumor development
Numerous studies have linked NATs to cancer and in particular NatA
is implicated in tumor development and cell survival. Naa10 is proposed
to act as both an oncoprotein and a tumor suppressor [21,129]. This fur-
ther manifests the complexity and difﬁculties, in particular related to
NatA functions, as they are so diverse and target a variety of signaling
pathways. In order to give a better overview of NATs involvement in
tumor development, this section is separated into an oncogene and
tumor suppressor section focusing onNaa10 andNaa15, aswell as a sec-
tion on the other NATs' (NatC-F) critical roles in tumor progression.
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Naa15, the auxiliary subunit of NatA, was initially identiﬁed in a
screen for differentially expressed genes in papillary thyroid carcinoma
(PTC)where it displayed elevatedmRNA levels [130]. Later, overexpres-
sion of Naa15 was found in gastric cancer [131], as well as elevated
Naa15 protein level in poorly or undifferentiated PTC [132] and neuro-
blastomas associated with a poor prognosis [133]. Naa15 was also
found downregulated during differentiation of embryonal endothelial
cells, pro-myeloid and myeloid leukemia cells [85,134], thus further
linking the Naa15 expression pattern to both differentiation status and
aggressiveness of tumors.
The role of Naa10 in cancer cells has been extensively studied and
not surprisingly, Naa10 appears co-regulated with Naa15 during differ-
entiation [134,135]. Different cancer types and tissue display elevated
levels of Naa10 expression including hepatocellular carcinoma [129],
colorectal cancer [136,137], lung cancer [137,138], breast cancer [137,
139] and prostate cancer [140]. Overexpression of Naa10 was also re-
ported in urinary bladder cancer, breast cancer and cervical carcinoma
[137]. AswithNaa15, a high expression of Naa10 correlates to a low sur-
vival rate and aggressiveness of tumors [136,138].
Several studies have proposed various molecular explanations for
Naa10's role in cancer development and cellular pathways regulating
cell proliferation and cell survival. Overexpression of Naa10 increased
cell proliferation in breast cancer cells by promoting the cells to
pass the G1/S and G2/M cell cycle checkpoints [139]. HeLa cells
depleted for NatA showed a reduced viability due to activation of p53-
dependent apoptosis [141], a phenotype also found in colon carcinoma
reporting a p53-independent growth inhibition [142]. Lung cancer cells
depleted forNAA10displayed reduced cell proliferation andG1-arrest in
agreement with a reduced Cyclin D1 expression [143]. This phenotype
was proposed to be mediated by suppression of cyclin D1 through
Naa10-mediated ε-acetylation of one or more lysine residues of β-
catenin, which is a known regulator of cyclin D1. It is also known that
Naa10 induces cyclin D1 transcription by activating c-Jun and c-Fos
(AP-1 proteins) via the extracellular signal-regulated kinases (ERK) 1/
2 pathway [144,145]. Gromyko and colleagues conﬁrmed this activation
of cyclin D1 in anaplastic thyroid carcinoma, but β-catenin acetylation
levels remained unchanged upon Naa10 depletion [142]. Naa10 onco-
genic properties are inﬂuenced by many of its interaction partners. An
example is the direct interaction between Naa10 and DNAmethyltrans-
ferase 1 (DNMT1)which facilitates DNMT1 binding to its substrate DNA
[138]. Typically, DNMT1 binds promoters of tumor suppressor genes
and silences their transcription by hypermethylation as shown for E-
cadherin. Naa10 also interacts with and acetylates the androgen recep-
tor (AR), which facilitates binding of AR to its targeted promoters and
enhances gene transcription of AR-regulated genes promoting tumori-
genesis [140]. This study reports that androgen induces the expression
of Naa10 in an AR-dependent manner, indicating a positive feedback
mechanism further explaining the oncogenic role of Naa10 in control-
ling proliferation, anchorage-independent growth and xenograft
tumor formation in prostate cancer.
Not surprisingly, the activity of Naa10 and potency to Nt-acetylate
proteins is regulated in response to the metabolic level of Ac-CoA. Can-
cer cells in general have a high metabolic rate [146,147]. The anti-
apoptotic factor Bcl-xL promotes cancer development by regulating
cell survival and inﬂuences the mitochondrial metabolism [148–150].
Studies by Yi et al. showed Bcl-xL-mediated regulation of Ac-CoA avail-
ability followed by reduced Nt-acetylation of essential apoptotic media-
tors [151]. Thus, regulation of protein Nt-acetylation provides a Bax/
Bak-independentmechanism for Bcl-xL to regulate apoptotic sensitivity
and promote cell survival. Activation of hypoxia inducible factor-1 (HIF-
1α) transcriptional complex during hypoxia promotes tumor survival
by induced angiogenesis, cell migration and resistance to chemotherapy
[152]. HIF-1α, shown by Lim and colleagues as a regulator of Naa10,
binds directly to Naa10 and blocks a following acetylation of β-catenin
and thus obstructs the Wnt signaling pathway [145]. Methioninesulfoxide reductase A (MSRA) plays a crucial role in protecting proteins
from oxidation and repairs damages caused by reactive oxygen species
(ROS), which also crucially affects tunorigenesis [2]. A study by Shin
et al. showed in vivo and in vitroNaa10 interaction with MSRA followed
by K49 acetylation of MSRA, which represses its enzymatic function
[153]. The authors suggest that Naa10 plays a crucial role in the cellular
response to oxidative stress by regulating theMSRA activity. In contrary,
an in vitro study of recombinant expressed proteins shows that Naa10
does not enzymatically acetylate lysine residues of Runx2, Myosin
light chain kinase (MLCK) and MSRA [154]. Instead, they demonstrated
in vitro non-enzymatic acetylation of these substrates by addition of Ac-
CoA, indicating a chemically driven lysine acetylation, leaving the deci-
pherment of this issue to upcoming studies (see Section 6.2).
Numerous cancer studies report an elevated expression level of
Naa10 and Naa15, the two subunits of theNatA complex. More interest-
ingly, this over-expression correlated with more aggressive tumors and
a poor patient survival rate. Naa10 and Naa15 involvement in tumori-
genesis were further demonstrated by their role in promoting cell
proliferation and cell survival as well as regulating cell metabolism.
2.7.2. Naa10 - a tumor suppressor?
Contrary to Naa10's oncogenic abilities, several studies indicate that
Naa10 has tumor suppressor properties. Yi et al. identiﬁed Naa10 in a
genome-wide RNAi screen as necessary for DNA damage-induced apo-
ptosis by caspase activation [155]. An elevated expression of Naa10 is
also implicated in reducing breast cancer cell growth through stabiliza-
tion of TSC2 by direct interaction and Nt-acetylation [74]. Stabilization
and increased abundance of TSC2 suppress the mammalian target of
rapamycin (mTOR) signaling pathway and thereby reduce cell prolifer-
ation. A high expression level of Naa10 has also been correlated to
smaller breast tumors, fewer lymph nodemetastases and a better prog-
nosis [74,156]. Zeng et al. further demonstratedNaa10 as a negative reg-
ulator of signal transducer and activator of transcription 5a (STAT5a), by
direct binding to STAT5a and downregulation of inhibitors for differen-
tiation 1 (ID1). Independent of its acetyltransferase activity, Naa10 in-
hibits cell migration, invasion and metastasis by antagonizing Janus
Kinase 2 (JAK2)-STAT5a signaling and lowering p65-activated
interleukin-1β expression [156]. The study byHua et al. further presents
Naa10 as a tumor growth and metastasis suppressor by binding of p21-
activated kinase (PAK)-interacting exchange factor (PIX) proteins, thus
preventing formation of the GIT-PIX-Paxillin complex and subsequent
activation of Rac1/Csc42 [157]. Yet, another mechanism presented by
Shin and colleagues reports that Naa10 inhibits cell motility by direct
binding ofMLCK and following acetylation of K608, thereby inactivating
the ability of MLCK to phosphorylate MLC [158]. Studies by Park et al.
showedNaa10 as required for doxorubicin NF-κB activation by its inter-
action with the receptor-interacting protein 1 (RIP1) [159]. Recently,
NAA10 expression in colon cancer was found regulated by microRNAs,
which target NAA10 for degradation [160].
These studies suggest Naa10 to have a more predominantly anti-
proliferative and pro-apoptotic function in certain types of tumor cells
in contrast to the numerous studies discussed in the previous section,
reporting a pure role as an oncogene.Without doubt, Naa10 is an impor-
tant protein with truly diverse functions, and the precise role of Naa10
in tumor development will remain as a major challenge for future stud-
ies. Studies need to focus more on the regulation of NatA and through
which mechanisms these anti-proliferative and pro-apoptotic proper-
ties are mediated in given tissues.
2.7.3. NatC, D, E and F in tumor development
Other NATs may also be involved in oncogenesis, although most
studies connecting NATs to cancer development focuses on NatA. The
NatB subunits found overexpressed in hepatocellular carcinoma are
implicated in cell proliferation and cell cycle progression [161]. While
depletion ofNAA25 caused cell death, depletion ofNAA20mainly results
in growth arrest. However, cells depleted for NatB displayed cell cycle
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sensitized cells to pro-apoptotic agents [56,161]. NatC knockdown
studies by Starheim et al. demonstrated a reduced cell proliferation
and p53-dependent caspase-mediated apoptosis [59]. Interestingly,
activation of p53 went through another phosphorylation pathway
than observed for NatA and NatB. In agreement, NatC was shown to
act via the p53-mediated pathway in glioblastoma cancers and Naa30
depletion reduced tumorigenic features [162]. Here, NatC regulated
the expression level of genes involved in cell cycle regulation, prolifera-
tion and apoptosis as well as genes involved in DNA repair and regula-
tion of protein kinases, probably as a consequence of Nt-acetylation.
NatD is downregulated in hepatocellular carcinoma, and shown to pro-
tect cells fromdrug induced apoptosis [163]. NatDNt-acetylates histone
H4, thereby regulating argininemethylation and ribosomal DNA silenc-
ing, and might act as a sensor for cell growth [104]. Although NatD is
downregulated in hepatocellular carcinoma, its overexpression en-
hances apoptosis in cancerous cells [163]. Depletion of NatD further
demonstrated the involvement of NatD in protecting cancer cells from
drug-induced apoptosis. Recently, depletion of NatD in colon cancer
was shown to induce p53-independent apoptosis by activating the mi-
tochondrial capsase-9-mediated apoptotic cascade [164]. NatE deple-
tion studies show that Naa50 is important for cell-cycle progression as
depletion leads toM-phase cell-cycle arrest [105]. Depletion studies fur-
ther demonstrate NatE function as essential for normal sister chromatid
cohesion and chromosome condensation [52,105,106]. Similarly, cells
depleted for NatF had abnormal chromosome segregation, which
might lead to genomic instability and aneuploid cells [24].
To sum up, NATs are involved in a multitude of signaling pathways
and shown to regulate cell-cycle and cell proliferation, cell survival, an-
giogenesis, apoptosis and to play an important role during chromosome
segregation. The emerging role and involvement of all six human NATs
in cancers or other pathologies are not surprisingwhen considering that
80% of all proteins are modiﬁed by these enzymes. NATs affect other
proteins either through direct Nt-acetylation of target substrate pro-
teins, or by protein-protein interactions and subsequent suppression
or activation. However, missing links exist and all NAT enzymes still de-
serve a signiﬁcant attention in order to give a complete mechanistic ex-
planation for the observed phenotypes.
3. Lysine acetylation
3.1. ε-Acetylation of lysine residues in general
3.1.1. The players involved in lysine acetylation
ε-amino lysine acetylation is involved in several cellular pathways
and is not limited to transcriptional regulation by histone modiﬁcation
alone [165]. Besides phosphorylation, it is perhaps the most abundant
and important PTM in cell signaling and metabolism. Lysine acetylation
is dependent on Ac-CoA, while a class of KDACs, the sirtuins, use NAD+
(nicotine adenine dinucleotide) as a co-substrate. These two metabo-
lites are important hubs of cellularmetabolism, and link cellular metab-
olism and cell signaling pathways (see Section 4) [165–167]. Three
classes of ‘players’ are involved in cell signaling by lysine acetylation:
KATs, KDACs, and proteins recognizing and binding acetyl-lysines.
Most of these acetyl-lysine binders contain the so called bromodomain
(~120 amino acids long sequence forming small helical interaction
modules), including KATs and transcription factors [168]. In contrast
to Nt-acetylation, lysine acetylation is reversible, making it a crucial
tool for the cell to activate and deactivate certain pathways. KDACs are
divided into two distinct groups with different catalytic mechanisms:
Zn2+-dependent HDACs (HDAC1–11) and NAD+-dependent sirtuins
(SIRT1–7) [14]. Besides KAT-catalyzed lysine acetylation, some acetyla-
tion events can also occur non-enzymatically via direct interaction of
the protein and Ac-CoA. This reaction is favored by high pH and high
Ac-CoA concentrations, conditions which certainly are present in mito-
chondria [169,170]. It has also been shown that other acyl-CoA orglycolytic intermediates can enzymatically or non-enzymatically bind
to lysine residues in certain conditions leading to formylation,
succinylation, propionylation, butyrylation, or crotonylation [167,171–
175]. They are mainly determined as histone modiﬁcations (e.g. K23 in
histone protein H3), but new non-histone target proteins such as p53,
p300 and CREB are constantly being identiﬁed [174,176]. Especially
propionylation and butyrylation are carried out by p300 and CREB.
Thereby, they are able to autopropionylate someof their own lysine res-
idues [175]. Further, it was demonstrated in Salmonella enterica that the
propionylation at position K592 of the propionyl-CoA synthetase en-
zyme PrpE results in its inactivation [177]. Interestingly, most of these
PTMs can be reversed by sirtuins, particular by SIRT1, SIRT2, and
SIRT5. Further, a balanced regulation between KATs and KDACs is cru-
cial for many cellular processes and especially for chromatin-based
transcriptional regulation [178].
3.1.2. The abundance of lysine acetylation
Lysine acetylation is evolutionarily conserved. Proteome-wide stud-
ies in E. coli and Saccharomyces cerevisiae demonstrated the importance
of this PTM in these organisms.Many acetylated proteins found in these
studies were involved in metabolism, translational regulation or stress
response. The amount of identiﬁed acetylation sites increases with the
complexity of the organism, comparable to Nt-acetylation events
[179–182]. In E. coli only 138 acetylation sites in 91 proteins have
been identiﬁed [180], whereas in S. cerevisiae 2878 acetylation sites
from 1059 proteins were determined. An organ-wide analysis of rat
tissues identiﬁed 15,474 tissue-speciﬁc modiﬁcations sites in 4541
proteins, associated with various cellular functions such as gene
expression, pyruvate, amino acid and glucose metabolism, apoptosis,
and membrane trafﬁcking [182]. Nevertheless, lysine acetylation is oc-
curring more frequently than phosphorylation in bacteria. Considering
the endosymbiotic theory, it is not surprising that lysine acetylation is
also more abundant in mitochondria of eukaryotic cells than other
PTMs [183,184]. When further comparing lysine acetylation with phos-
phorylation, it is remarkable that lysine acetylation sites are often found
in highly structured regions (α-helices as well as β-sheets), whereas
phosphorylations mainly occur in unstructured and ﬂexible protein re-
gions [165,185].
3.2. The lysine acetyltransferases (KATs)
3.2.1. The KAT families
Histone acetylation and the involvement of particular enzymes
(KATs) were ﬁrst discovered in 1964 by Allfrey and colleagues [13]. So
far, 17–22 ‘classical’ KATs have been identiﬁed in the human genome
[14,15,167,186]. The exact number of KATs is controversial due to differ-
ent indications in literature. The human genome (HUGO) gene nomen-
clature committee lists 17 different genes as KATs. This number refers to
genes that have been identiﬁed and characterized as KATs as their main
catalytic activity. Not listed are enzymes, which display KAT activity in
addition to their previously characterized and described enzymatic ac-
tivities, and when including these, the number of human KATs reaches
22. The KATs can be grouped into three major families: the GNAT (see
Section 2.2) family, the MYST family and the p300/CBP (CREB-binding
protein) family [15,187]. Table 1 lists the ‘classical’ KATs and additional-
ly some examples of enzymes displaying additional KAT activity. The ac-
ronym MYST comes from the ﬁrst four identiﬁed members: human
monocytic leukemia zinkﬁnger protein (MOZ), something about silenc-
ing 3 (Ybf2), now Ssa3; Ssa2, both from yeast, andmammalian HIV Tat-
interacting 60 kDa protein (TIP60) [188]. Recent studies have identiﬁed
new KATs or have demonstrated that proteins with a known non-KAT
catalytic activity are able to transfer an acetyl moiety to speciﬁc sub-
strate lysines. Examples include GCN5L1 and themitochondrial thiolase
ACAT1 [189]. Most KATs belong tomultiprotein complexeswith various
associated subunits, which deﬁne their catalytic activities and substrate
speciﬁcities, especially in the case of histone acetylation [190]. The
Table 1
Members of the human HAT/KAT families (see Refs. [15,186,188,269]).
Family HAT/KAT New name Subcellular localization Representative substrates Swiss-Prot accession no.
GNAT HAT1 KAT1 Nucleus H2A, H4 O14929
GNAT GCN5 (GCN5L2) KAT2A Nucleus H3, CEBPB Q92830
GNAT PCAF KAT2B Nucleus H3, H4, ACLY Q92831
p300/CBP CBP KAT3A Nucleus/Cytoplasm H2A, H2B, H3, H4, NCOA, FOXO1 Q92793
p300/CBP P300 KAT3B Nucleus/Cytoplasm H3, FOXO1, HDAC1, SIRT2, ALX1 Q09472
TAF1 (TAFII250) KAT4 Nucleus H3, H4 P21675
MYST TIP60/PLIP KAT5 Nucleus/Cytoplasm H2A, H4, FOXP3 Q92993
MYST MOZ/MYST3 KAT6A Nucleus H3, H4, p53, RUNX2 Q92794
MYST MORF/MYST4 KAT6B Nucleus H3, RUNX2 Q8WYB5
MYST HBO1/MYST2 KAT7 Nucleus H4 O95251
MYST MOF/MYST1 KAT8 Nucleus H4, p53 Q9H7Z6
GNAT ELP3 KAT9 Nucleus/Cytoplasm H3, H4, α-tubulin Q9H9T3
TFIIIC90 (GTF3C4) KAT12 Nucleus H3 Q9UKN8
SRC-1 (NCOA1) KAT13A Nucleus H3, H4 Q15788
SRC-3 (TRAM1, NCOA3, ACTR) KAT13B Nucleus/Cytoplasm H3, H4 Q9Y6Q9
SRC-2 (TIF2, GRIP1, bHLHe75, NCOA2, P160) KAT13C Nucleus H3, H4 Q15596
CLOCK KAT13D Nucleus/Cytoplasm ARNTL/BMAL1, NR3C1/GR O15516
ATF-2 (CREB2, CREBP1) Nucleus/Cytoplasm H2B, H4 P15336
GNAT ATAT1 Cytoplasm/Membrane α-tubulin Q5SQI0
ACAT1 Mitochondria PDP P24752
NAT10 Nucleus Histones, α-tubulin Q9H0A0
GCN5L1 (BLOC1S1) Mitochondria ATP5A1, NDUFA9 P78537
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them to their appropriate localization, display different domains such
as bromodomains (recognizing acetylated lysines), chromodomains,
Tudor domains and WD40 repeats (recognizing chromatin structures
and non-acetylated histone proteins). PHD ﬁnger domains are normally
binding non-acetylated lysine. However, it was demonstrated that a
tandem PHD ﬁnger domain of the human chromatin remodeling pro-
tein DPF3b is able to bind to acetylated K14 of H3 (H3K14ac) [191]. In
addition to the enzymes belonging to the three major KAT families,
KAT activity could be deciphered for several further proteins (for a
detailed list of all human KATs and their associated complex subunits
see Ref. [192]).
3.2.2. The manifold targets of KATs
Histone proteins are not the only known substrates of KAT
complexes. Many different transcription factors and transcriptional co-
regulators becomemodiﬁedbyKATs. These are partly general transcrip-
tion factors such as TFIIB or TFIIE, but also proteins of speciﬁc cellular
signaling pathways like p53, β-catenin, NF-κB, MyoD or Rb [188]. Inter-
estingly, RNA molecules also undergo post-transcriptional acetylation.
Elp3 mediates this modiﬁcation of nucleosides especially towards
tRNAmolecules [193]. Consequently, KATs are crucial modiﬁers for epi-
genetic and transcriptional regulation. Besides the nuclear substrates,
cytosolic proteins also belong to the great substrate pool of KATs (see
Sections 3.5 and 3.6). Recently, it was shown that NAT10 (not to bemis-
taken for the N-terminal acetyltransferase Naa10), whichwasﬁrst iden-
tiﬁed as a nucleolar KAT involved in H2B and H4 acetylation, is involved
maintaining the structural integrity of the mitotic midbody organelle
during the telophase [194]. Similar to Elp3, NAT10 is additionally able
to facilitate acetylation of cytidine residues of rRNA and tRNA [195].
The proteins of the p300/CBP family were ﬁrst identiﬁed as transcrip-
tional co-activators and later as interaction partners of adenoviral-
transforming protein E1A [196]. They are involved in the regulation of
cell growth and development, including the NF-κB, Notch, TGF-β, p53
and Rb-cell signaling pathway [197,198]. These represent tumorigenic
pathways, thus demonstrating a critical role of p300/CBP in cell trans-
formation and oncogenesis (see Section 5.1) [198,199]. Interestingly,
KAT autoacetylation is common and seems to play distinct roles for
different KATs. The histone acetyltransferases p300 and CBP, acetylating
histone and non-histone proteins alone or in the PCAF complex, can be-
come autoacetylated at various lysine residues. p300 is autoacetylated
at ﬁve lysine positions at the C-terminus resulting in an increasedbasal activity [200]. The conformational alterations induced by
autoacetylation of CBP feature a crucial requirement for H3K53 binding
and acetylation [201,202]. In both cases autoacetylation leads to an in-
creased KAT activity. Autoacetylation of the MYST proteins Esa1
(yeast) and MOF (human) has a similar effect. Both enzymes become
autoacetylated at lysine residues, which are part of their catalytic do-
main. These acetylation reactions are a precondition for substrate bind-
ing and subsequent acetylation [203].3.3. Lysine deacetylases
3.3.1. The four classes of KDACs
Lysine deacetylases (KDACs) or histone deacetylases (HDACs) were
ﬁrst identiﬁed in 1995, acting on acetyl-lysines of histone proteins
[204]. Later their function has also been dissected for several other
proteins and cellular functions [205,206]. Although most of these
deacetylases display activity towards multiple substrates, and except
for the sirtuins (SIRT1–7), they are still known as HDACs (HDAC1–11).
The KDAC family has phylogenetically been divided into four classes in
higher eukaryotes. Class I, II and IV are Zn2+-dependent
amidohydrolases, whereas class III (also called sirtuins) uses NAD+ as
co-substrate for its catalytic activity (Fig. 1C) [207]. Class IV has only
one known representative, HDAC11, which differs phylogenetically
from the Zn2+-dependent yeast proteins Rpd3 (class I) and HDA1
(class II), aswell as from theNAD+-dependent Sir2 homolog, and there-
fore forms its own subclass [208]. Noteworthy, class I and II share a high
homology in their catalytic domains [209]. The Zn2+-dependent KDACs
are mainly localized in the nucleus and cytoplasm, whereas sirtuins are
additionally present in mitochondria (Table 2) [167,210]. Substrates of
KDAC class I and II are in general histone molecules and various
transcription factors. They are normally associated with transcriptional
repressor complexes in the nucleus such as Sin3, NuRD/NRD/Mi2,
CoREST, and SMRT/N-CoR. The only exception is HDAC8, which is active
as a monomer. Nevertheless, the class II members HDAC6 and HDAC10
have various regulating roles in the cytoplasm. Tubulin, cortactin and
Hsp90 are only some targets of HDAC6 (see Sections 3.5 and 3.6)
[210–212]. HDAC11 (class IV), which is predominantly localized in the
nucleus, triggers the decision between immune activation and immune
tolerance by regulating the interleukin 10 expression in antigen-
presenting cells. This is to date its only known physiological function
[213].
Table 2
Members of the HDAC/KDAC family and their subcellular localization (see Refs. [215,455–457]).
Class Member Catalytic mechanism Subcellular localization Representative substrates Swiss-Prot accession no.
I HDAC 1 Zn2+ dependent Nucleus H2A, H2B, H3, H4, RelA, AR Q13547
I HDAC2 Zn2+ dependent Nucleus H2A, H2B, H3, H4, TSHZ3 Q92769
I HDAC3 Zn2+ dependent Nucleus H2A, H2B, H3, H4, NF-κB, PCAF, STAT1, RelA O15379
I HDAC8 Zn2+ dependent Nucleus/Cytoplasm H2A, H2B, H3, H4, p53, ERRα Q9BY41
II HDAC4 Zn2+ dependent Nucleus/Cytoplasm H2A, H2B, H3, H4, HIF1α, p53, DNAJ88 P56524
II HDAC5 Zn2+ dependent Nucleus/Cytoplasm GATA-2, GCMa Q9UQL6
II HDAC6 Zn2+ dependent primarily Cytoplasm Cortactin, α-tubulin, HSP90 Q9UBN7
II HDAC7 Zn2+ dependent Nucleus/Cytoplasm PLAG1 Q8WUI4
II HDAC9 Zn2+ dependent Nucleus/Cytoplasm ATDC Q9UKV0
II HDAC10 Zn2+ dependent primarily Cytoplasm HSP70, PP1 Q969S8
III SIRT1 NAD+ dependent Nucleus P53, FOXO1, HSF1, KAT7, CBP Q96EB6
III SIRT2 NAD+ dependent Cytoplasm α-tubulin Q8IXI6
III SIRT3 NAD+ dependent Mitochondria GDH, Ku70, MRLP10, AceCS2 Q9NTG7
III SIRT4 NAD+ dependent Mitochondria GLUD1 Q9Y6E7
III SIRT5 NAD+ dependent Mitochondria CPS1, cytochrome c Q9NXA8
III SIRT6 NAD+ dependent Nucleus H3K56ac, RBBP8 Q8N6T7
III SIRT7 NAD+ dependent Nucleolus H3K18ac, PAF53 Q9NRC8
IV HDAC11 Zn2+ dependent primarily Nucleus H2A, H2B, H3, H4 Q96DB2
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The sirtuins need NAD+ as co-substrate for deacetylation, and it
was shown via the use of various inhibitors that nicotinamide and
2′ or 3′-O-acetyl-ADP-ribose are formed as byproducts (Fig. 1C)
[214]. The name sirtuins is derived from its ﬁrst found representative
sir2 (silent information regulator 2) in yeast. There, it is important
for chromatin silencing in different loci and additionally plays a
role in yeast longevity [215,216]. In mammals, seven different
sirtuins (SIRT1–SIRT7) have been identiﬁed to date. They are
localized in various cell compartments. SIRT1, SIRT6 and SIRT7 are
localized in the nucleus, whereas SIRT2 is active in the cytoplasm. A
special characteristic of SIRT3, SIRT4 and SIRT5, which distinguish
them from other KDACs, is that they are acting in mitochondria and
subsequently affecting metabolic processes (Table 3). Especially,
SIRT3 displays a great inﬂuence on the intermediate metabolism by
deacetylating several of its enzymes and regulating their activity
(see Section 4) [217,218]. SIRT4 has a unique role in mammals
because it displays an ADP-ribosyltransferase and lipoamidase
activity in addition to its deacetylase activity. Thereby, its
catalytic activity towards lipoyl- and biotinyl-lysine is higher
than towards acetyl-lysine [219]. It transfers further ADP-ribose on
glutamate dehydrogenase I (GLUD1), repressing its activity, and
thus displaying an important role in caloric restriction [220].
The non-mitochondrial sirtuins are also involved in metabolic
processes, especially glucose metabolism. This was demonstrated
for SIRT1, SIRT6 and SIRT7 (see Section 4) [221–223]. Additionally,
SIRT7, which is active in the nucleolus, was shown to speciﬁcally
deacetylate the K18 on histone protein H3 (H3K18Ac), subsequently
maintaining tumorigenicity of human cancer cells [224].Table 3
Acetylation-modulated intermediary metabolic enzymes and the effect on their activity.
Enzyme Process Cellu
Phosphoenol-pyruvate carboxykinase Gluconeogenesis Cyto
AceCS1 Acetyl CoA formation from acetate Cyto
AceCS2 Acetyl CoA formation from acetate Mito
LCAD β-oxidation of fatty acids Mito
EHHADH β-oxidation of fatty acids Mito
MDH Citric acid cycle/urea cycle Mito
SDH Citric acid cycle Mito
ASL Urea cycle Cyto
CPS1 Urea cycle Mito
OTC Urea cycle Mito
PDHA1 Acetyl-CoA formation Mito
Aconitase CAC Mito
a In addition to listed references see reference [464].3.4. Role of histone acetylation in general epigenetic regulation
3.4.1. General aspects of histone modiﬁcations
The ﬁrst proteins discovered to be acetylated were histones [225].
All four different histone proteins, H2A, H2B, H3 and H4 become acety-
lated by different HATs (Table 1). Together with DNA, histone proteins
form the so called nucleosomes. One nucleosome consists of about
150–200 bps of DNA,whichwraps itself almost two times around a pro-
tein core that is formed by two copies of each of the four histone mole-
cules [226]. Chains of nucleosomes assemble to deﬁned chromatin
structures, which can be transcriptionally active or inactive. The histone
molecules are modiﬁed by various PTMs, of which phosphorylation,
methylation and acetylation play themost crucial roles for DNA accessi-
bility and transcriptional regulation. The PTMs, and especially histone
acetylation, determine the histone assembling as well as the folding
and compactness of the DNA-histone interaction and therefore present-
ing a switch between permissive and repressive chromatin structure
[227]. After synthesis, the histone proteins are transiently acetylated,
determining their localization and deposition in the nucleus. This ap-
plies especially to K5 and K12 in newly synthesized H4 and is more
species-dependent for histone H3 [190,228]. This speciﬁc acetylation
pattern recruits chaperones, assisting in the formation of the nucleo-
some. After binding to the DNA, histones are deacetylated, and re-
acetylated again in a different pattern, which is essential for chromatin
functionality [190,229].
3.4.2. Histone acetylation leads in general to transcriptional activation
In general, a high degree of acetylation correlates with increased
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loses its positive charge and thus the ability to form salt bridges
with the negatively charged phosphate backbone of DNA [230].
This leads to an open, lightly packed chromatin structure (euchro-
matin), and consequently to an increase of gene transcription. The
opposite, densely packed form of chromatin is called heterochroma-
tin (Fig. 4A) [231,232]. This was shown for various acetylated lysines
at different positions on different histone molecules. It was demon-
strated that residues 14–23 of the tail of histone 4 are particularly
important for ﬁber formation and dense chromatin structure.
Acetylation of these residues, and especially acetylation of H4K16,Fig. 4. Acetylation and regulation of histone acetylation. A) Reversible acetylation of histone tail
concomitantly loosens the compactness of the chromatin structure. This leads to conformation
acetylation rate is normally associated with an increased transcriptional activity. B) Histone tai
(TFs) or chromatin remodeling complexes (CRCs) via bromodomains. Bromodomains consist of
regulated by speciﬁc repressors, recruiting histone deacetylases (HDACs). Shown here is the SA
genomic regions and activate the deacetylase activity of HDAC3. The two SANT-domains of SMR
domains with the preferentiality for unacetylated histone tails. Thereby, they block substantial
repression.disrupts the chromatin structure and results in transcription activation
and maintains the euchromatin form [233]. Similar results were
observed for acetylation of H3K56, H3K64 and H3K122 [230].
H3K56ac is speciﬁcally targeted by Sir2 in yeast, keeping H3K56 in a
hypoacetylated state and maintaining heterochromatin structure near
transcriptionally silent regions such as telomers [234]. In contrast to
the abovementioned acetylated lysines, which disrupt histone-DNA
interaction, H4K91 acetylation directly affects histone-histone interac-
tion, in particular H2A-H2B-dimerization. Thus, H4K91ac, weakens the
complete histone octamer and leads to alterations of the heterochroma-
tin structure [235].s by various histone acetyltransferases (HATs) weakens the DNA-histone interactions, and
al changes from heterochromatin to the more open euchromatin structure. A high histone
ls containing acetylated lysine residues are recognized and bound by transcription factors
around 110 amino acids and form a fourα-helices bundle. C) Transcriptional repression is
NT-containing repressor SMRT and the corepressor N-CoR. Both recruit HDAC3 to speciﬁc
T are part of the functionality for HDAC3's deacetylase domain and act as histone binding
ly acetylation sites for re-acetylation by HATs and maintain in this way the transcriptional
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chromatin-modifying enzymes
Histone acetylation enables the binding of bromodomain-containing
proteins and transcription factors, expanding the number of regulatory
factors. In humans, the bromodomain family consists in total of 46
different proteins (Fig. 4B) [236,237]. In contrast to gene transcription
activation by KATs, KDACs repress transcription by histone
deacetylation. A histone in a hypoacetylated state promotes binding of
SANT-domain containing enzymes, mainly found in transcriptional co-
repressors [238]. The SANT-domain enzymes, preferentially binding
unacetylated histone tails, are part of the HDAC3 complex, which
guarantees andmaintains the recruitment of associated corepressors
at speciﬁc genomic sites such as nuclear receptor corepressor (N-
CoR) and silencing mediator of retinoid and thyroid receptors
(SMRT) (Fig. 4C) [239]. Nevertheless, HDACs can also play a role in
the proper transcription initiation at active gene sites as demonstrat-
ed for the Hos2 deacetylase in yeast [240]. For other active genes,
HDACs repress the transcription initiation or are recruited to prepare
for repression [190,241]. Altogether, the effects of KATs and KDACs
on the nucleosome and concomitantly gene transcription depend
on the genomic site they act on as well as the different complexes
they form. Several transcription regulating complexes share the
same KATs and KDACs but differ completely in their functions. To
understand the regulation and speciﬁcity of these complexes is part of
further investigations.Fig. 5. Acetylation of cytoskeleton. Acetylation of cytoskeletal proteins (A) and (B) plays a cruci
dimeric isoforms ofG-actin,α-,β-, andγ-actin. All three isoforms can be acetylated. Itwas show
less restructuring. B) Additionally, proteins such as cortactin, which modulate actin polymeriz
different lysine residues by p300/PCAF and be deacetylated again by SIRT1 or HDAC6. The ace
motility.3.5. Acetylation of cytoskeletal proteins
Besides histones, cytoskeletal proteins are another crucial family
which is targeted by KATs. Cytoskeletal complexes play an important
role in cell shape, intracellular cargo transport, cell division and
motility. The monomeric cytoskeletal G actin proteins can polymer-
ize to ﬁlamentous F actin and form the versatile microﬁlaments in
eukaryotic cells. Three different isoforms of G-actin exist, α-, β-,
and γ-actin, and it was demonstrated that all three isoforms can be
acetylated. Thereby, it was shown that lysine acetylation of γ-actin
at position 61 increases the ﬁber stability (Fig. 5A) [242,243]. Not
only actin or myosin proteins themselves are acetylated, but also
proteins that interact and regulate these molecules such as cortactin.
Cortactin binds to dynamic F-actin bundles promoting polymeriza-
tion and branching [244]. When cortactin becomes acetylated by
p300 or PCAF at nine different positions, its binding to actin is
inhibited, provoking a direct effect on cell motility. This process is re-
versed by cortactin deacetylation via SIRT1 or HDAC6 (Fig. 5B) [245,
246]. The regulation of the cytoskeleton by acetylation was further
conﬁrmed by studies which demonstrated that HDAC6 is a major ef-
fector of this system [211,247]. HDAC6 interacts with two actin poly-
merization controlling proteins, mDia1 and mDia2, and therefore
directly interferes with actin stability [248]. Another group of impor-
tant cytoskeletal ﬁlaments are microtubules, which are formed by
repeating α- and β-tubulin heterodimers. α-tubulin was shown toal role in cell growth, stability andmigration. A)Microﬁlamentous F-actin is formed by the
n that the acetylation ofγ-actin at thepositionK61 results in an increasedﬁber stability and
ation and branching, are targets for acetylation. Cortactin itself can be acetylated at nine
tylation abrogates the ability of cortactin to bind to F-actin, thus directly inﬂuencing cell
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is again targeted by HDAC6 [249,250]. Later it was shown that SIRT2
is also able to deacetylate α-tubulin acK40 [251]. Tubulins are one of
many substrates HDAC6 and SIRT2 share. The acetylation of
α-tubulin itself is catalyzed by several KATs, such as NAT10, ELP3,
GCN5, and ATAT1 [252]. With advancements in mass spectrometry,
additional acetylation sites came along [165]. The counterpart,
β-tubulin, is also acetylated which affects the kinetics of tubulin
polymerization [253]. Nevertheless, tubulin acetylation does not
seem to directly affect architecture or tubulin conformation per se,
but rather recruits tubulin binding proteins and affects their
localization [254].Fig. 6. Exemplary substrates regulated by lysine acetylation. A) Regulation of p53 activity by ace
acetylated at position K120 and K164 by p300/CBP and TIP60/MOF, MDM2 and p21 binding ar
arrest. Two possible fates for p53 are now possible: further hyperacetylation of the C-termin
transcriptional repression and subsequent cell survival. B) The transcription factor FOXO1 is
which enables target genes discrimination, transcriptional activation and shuttling between c
FOXO1 phosphorylation. This enables the binding of the protein 14-3-3, and thus abrogatin
through acetylation. MYC recruits the SAGA complex to chromatin, where it acetylates histone3.6. Further important non-histone substrates
The number of newly identiﬁed acetylation sites, belonging to pro-
teins besides the well characterized histones and cytoskeletal proteins,
is constantly increasing [167]. Several of these proteins have been stud-
ied in detail such as HMG proteins, c-Myc, estrogen and androgen re-
ceptors, E2F/Rb and many more [14]. The ﬁrst recognized non-histone
KAT substrate was the tumor suppressor p53 [14,255]. p53 is a key reg-
ulator of cellular processes and becomes enormously important under
various types of stress. Although p53 is targeted by several different
PTMs, acetylation seems to play a key role in activation. Three important
acetylation sites, K120 (acetylated by TIP60/MOF), K164 and the C-tylation. Mdm2 binds to unacetylated p53 ﬂagging it for degradation.When p53 becomes
e abolished, resulting in the activation of p53-responsive genes and concomitant cell cycle
us leading to the activation of apoptotic genes or deacetylation by HDAC1 resulting in
acetylated by p300/CBP at multiple sites (deacetylation catalyzed by SIRT1 and SIRT2),
ytoplasma and nucleus. FOXO1 acetylation recruits Akt kinase and results in subsequent
g nuclear import. C) GCN5, the catalytic subunit of the SAGA complex, stabilizes MYC
s and enables transcription of MYC response genes.
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anism [256]. p53 acetylation at these sites completely abolish the bind-
ing to p21 as well as the interaction with its repressor Mdm2, thus
leading to transcriptional activation of p53-responsive genes and cell
growth arrest [257]. Hyperacetylation of p53 results in an apoptosis
and cell death. Vice versa, Mdm2 recruits HDAC1 and/or SIRT1 and con-
comitantly promotes the deacetylation of p53 again and thereby
abolishing transcriptional activity (Fig. 6A) [257,258]. The small
GTPase-binding protein Ran is also regulated by lysine acetylation. It is
involved in many cellular processes such as actin cytoskeleton interac-
tions, formation of the mitotic spindle, and nucleo-cytoplasmic trans-
port [259]. Five distinguished acetylation sites in human have been
identiﬁed, displaying various effects on the protein [165]. Acetylation
of Ran determines its subcellular localization, its ability to bind to nucle-
ar transport proteins aswell as the GTP hydrolysis, and thusmakes acet-
ylation the tool of choice for Ran controlling [260]. Besides the
transcriptional regulation by histone acetylation, a series of transcrip-
tion factor families become lysine acetylated effecting their activity
and DNA binding abilities. Two of these transcription factors are NF-κB
(family of ﬁve proteins in mammalian cells) and FOXO (belongs to the
major family of forkhead box O transcription factors) [261,262]. Both
transcription factors regulate important subsets of cell functionality
and become reversibly acetylated by p300/CBP at multiple sites
(Fig. 6B) [263,264]. These acetylation events affect not only the tran-
scriptional activity but also the selection of regulated genes [262,265].
In the case of FOXO1, acetylation also regulates the localization and
shuttling between cytoplasm and nucleus by recruiting the kinase Akt.
Akt phosphorylates acetylated FOXO1 concomitantly resulting in bind-
ing of the protein 14-3-3, and thus inhibiting nuclear import [167].
Chaperones recognize aggregation-prone proteins and assist their fold-
ing. Due to upregulated gene expression upon heat stress,many chaper-
ones are called heat shock proteins (Hsps). The most abundant and
complexHsp in eukaryotic cells is theATP-dependentHsp90 [266]. It in-
teracts with hundreds of different client proteins like AKT, c-Raf, c-Src,
mineralocorticoid receptor and glucocorticoid receptor [266–268]. The
activity of Hsp90 and thematuration of its substrates are also partly de-
pendent on the acetylation status of Hsp90. It was demonstrated that
Hsp90 can be acetylated at several lysine residues and that its activation
is mediated by deacetylation via HDAC6 [269,270]. Thereby, K294 in
Hsp90 stands out because its deacetylation is crucial for co-chaperone
and client binding [271].3.7. Physiological roles of ε-acetylation
3.7.1. Lysine acetylation and regulation of intracellular pH
Targeted acetylation of lysine residues of signaling proteins and in
particular histone proteins at speciﬁc genomic loci is linked to a tight reg-
ulation of essential all types of DNA-templated processes as transcription,
replication, recombination, repair, translation and formation of special-
ized chromatin structures [272]. As such, the consequences of protein ly-
sine acetylation are tremendous and affect a range of cellular signaling
pathways as well as metabolism, stress responses, apoptosis and mem-
brane trafﬁcking. Not surprisingly, histone acetylation is linked to regula-
tion of intracellular pH (pHi) [273]. Histone acetylation and deacetylation
occurs rapidly and continuously throughout the genome, thus consuming
Ac-CoA and generating negatively charged acetate anions. As pHi de-
creases, histones become hypoacetylated in a HDAC-dependent manner
and the released acetate anions are co-exported with protons out of the
cell by the proton (H+)-coupled monocarboxylate transporters (MCTs),
preventing further reduction in the pHi. Conversely, histones become
hyperacetylated as pHi increases, a typicalmechanism in rapidly prolifer-
ating cells. Furthermore, different sites of histone acetylation respond
differently to pH alterations as shown with H4K16ac and H3K18ac,
where H3K18ac seems to be more unaffected by pH changes than
H4K16ac [273].3.7.2. Lysine acetylation and cognitive decline
Dysregulated acetylation is a common feature in neurodevelopmental
disorders, neurodegeneration and aging. Histone acetylation is triggered
by several forms of neuronal activity. Potassium chloride-mediated neu-
ronal depolarization, and stimulation by dopaminergic, cholinergic and
glutamatergic pathways all increase the acetylation of H2B, H3K14 and
H3S10 [274,275].In these cases, all changes in histone acetylation
occurred in parallel to phosphorylation events and direct activation of
the MAPK-ERK-pathway [276,277], indicating a crosstalk between
H3K14 acetylation and H3S10 phosphorylation events [272,277]. Neuro-
nal activity also starts a positive-feedback loop of HDAC2 and brain-
derived neurotropic factor (BDNF). Thus, a dissociation of HDAC2 from
chromosomes leads to hyperacetylation of histones and subsequent
neurotrophin-dependent gene expression [278]. Histone acetylation
and deacetylation events and their implications in neuronal activity, syn-
aptic plasticity and long and short-time memory promoting properties
are reviewed in [279].
An aging brain is typically associated with cognitive decline.
Hypoacetylation of neuroplasticity genes lead to transcriptional down-
regulation of genes essential for synaptic maintenance, function and
neurotransmission. Studies from aging mice and rat brains have
shown a reduced acetylation level of H3K9 and H4K12 as well as in-
creased HDAC2 expression, the latter resulting in a hypoacetylated
BDNF promoter-region [280–283]. In fact, a perturbed HDAC2-BDNF
feedback loop has been suggested as a common feature of aging and
neurodegeneration. A recent study additionally demonstrated in mid-
life-aged ﬂies that deregulation of the metabolism with elevated Ac-
CoA levels and subsequent higher histone and protein acetylation levels
result in a decreased life span. Reducing the Ac-CoA levels or inhibiting
KAT7, which acetylates H4K12, promoted longevity in these ﬂies [284].
Hypoacetylation of repeat-derived transcripts were also found in aging
mice brains [285]. A reduced histone acetylation might help to silence
these repeats and thereby protect against several brain disorders such
as Huntington's disease and fragile X syndrome [286,287]. Furthermore,
a reduced H3 and H4 acetylation and increased expression of several
HDACs (HDAC1, 2, 3, 8 and 10) are associated with stress responses in
animals [288]. Followed by increased DNAmethylation of the promoter
regions of the glucocorticoid receptor gene (GR; Nr3c1) and a reduced
GR transcription, this leads to a heightened stress response in the ani-
mals [289].
3.7.3. Aberrant lysine acetylation causes developmental defects
The importance of a tight regulation of acetylation and deacetylation
events is further highlighted by the histone deacetylases' many roles in
early development. Deletion of eachmember of class I HDACs in mice is
lethal. HDAC1-null mice display proliferation defects and growth retar-
dation and die before embryonic day 10 [290,291]. HDAC1 regulate spe-
ciﬁc gene programs by activating or repressing certain promoters in
embryonic cells. Modest hyperacetylation of H3 and H4 were found in
embryonic HDAC1-deleted stem cells as well as upregulation of the
cyclin dependent kinase inhibitors p21 and p27 [292]. Furthermore,
deletion of HDAC1 in zebraﬁsh causes skeletal and neuronal defects
that are lethal for the organism. The affected HDAC1-target genes
were shown to belong to the Wnt signaling pathway [293–297].
HDAC2-null mice have severe cardiac malformations, bradycardia and
die within the ﬁrst 24 h of birth [290]. The excessive cardiac
proliferation was linked to the missing HDAC2 inhibition of the
homeodomain-only protein (HOP), however a complete mechanistic
explanation for all transcriptional targets of HDAC2 remains unknown
[298–300]. Importantly, HDAC1 and HDAC2 have redundant functions
in cardiac growth and development, and regulate genes essential for
Ca2+ ﬂux and contractility [290]. HDAC3 mutant mice show gastrula-
tion defects and die before embryonic day 9 [301–303]. Defects in
DNA double-stranded break repair are associated with loss of HDAC3
as well as a dysfunctional lipid- and cholesterol-homeostasis [302,
303]. All class II HDACs inﬂuence the expression and function of the
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ways. HDAC4 has a central role in formation of the skeleton by regulat-
ing Runx2 andMEF2C transcription factor [304–306], while HDAC5 and
9 are essential for the control of cardiovascular growth and differentia-
tion by regulating transcriptional factors such as themyocardin (MYCD)
and calmodulin-binding transcriptional activator 2 (CAMTA2) aswell as
the serum response factor [307]. It is interesting to note that HDAC5 and
9 have redundant roles in regulating cardiac growth, as shown in
response to cardiac stress that typically activates the calcineurin and
calcium/calmodulin-dependent protein kinase (CaMK)-protein kinase
D (PKD) pathways which results in phosphorylation of HDAC5 and 9,
nuclear export and consequently activation of slow myoﬁber genes
[308–310]. Importantly, HDAC1, 2 and 3 regulate cardiomyocyte differ-
entiation and heart muscle lipid metabolism while HDAC5 and 9 are
functional redundant and pivotal for vertebrate heart tube formation
and growth by activation of the Wnt/β-catenin signaling pathway and
following bmp4 and notch1b expression [311]. HDAC6 is the main
HDAC shown to deacetylate tubulin and has essential functions modu-
lating the cytoskeletal dynamics and misfolded protein responses
[312]. However, there exists some redundancy with HDAC10. HDAC7
is essential in endothelial cells and tightly controls the function of
MEF2. Loss of HDAC7 is lethal and results in rupture of blood vessels,
pericardial oedema and haemorrhaging, consequently due to lack of
MEF2 repression and thereby upregulation of the matrix metallopro-
teinase 10 (MMP10) as well as a downregulation of the tissue inhibitor
of metalloproteinase 1 (TIMP1) [313]. A dysregulated HDAC7 control of
MMP10 is implicated in several human diseases such as atherosclerosis,
aneurysm, myocardial infarction and tumor angiogenesis [314,315].
Hdac8 knockouts die within 4–6 h after birth due to deﬁciency of cranial
neural crest cells [316]. Interestingly, HDACs are important for both the
glucose homeostasis and insulin resistance and as such shown to regu-
late diabetes as reviewed in [317] (Section 5.1).
The sirtuins are pivotal in maintaining the genomic integrity and
target different histones as exempliﬁed by H4K16ac, H3K9ac, K3K56ac
and H3K18ac, but also target structural proteins, enzymes as well as
non-histone components of the chromatin machinery [318]. They are
involved in regulation of transcription, metabolism, cell cycle control,
inﬂammation and found to suppress several age-associated diseases in-
cluding cancer and metabolic pathologies [319,320]. The sirtuins func-
tional mechanism and role for diseases are covered with more details
in Sections 4 and 5.4. Metabolic regulation of and by protein lysine acetylation and
deacetylation
4.1. Protein acetylation depends on acetyl-CoA, the concentration of which
ﬂuctuates
Most cellular ATP is derived from Ac-CoA, which is produced by
several sources: glycolysis from pyruvate by pyruvate dehydrogenase;
β-oxidation of fatty acids; from citrate by Ac-CoA-citrate lyase (ACL);
and from acetate, catalyzed by Ac-CoA synthetase. Pyruvate
dehydrogenase, as well as the citric acid cycle components, and thema-
chinery which catalyzes β-oxidation, are found in the mitochondria.
ACL acts on cytosolic citrate which is shuttled out of the mitochondria.
Ac-CoA synthetases are feedback-regulated by reversible inhibitory
acetylation. Different isoforms of Ac-CoA synthetase (AceCS1 and
AceCS2) exist. Respectively, they are found in the cytosol and in themi-
tochondria, and deacetylated by SIRT1 and SIRT3 [321]. This study did
not identify the AceCS1/2 acetyltransferases and, to our knowledge,
these have yet to be identiﬁed. The cytosolic and nuclear pools of
Ac-CoA are free to exchange, and are used in acetylation of histones
and non-histone proteins, as well as lipid, cholesterol and amino acid
synthesis. Mitochondrial Ac-CoA, on the other hand, is principally
involved in oxidation (reviewed in [322]).In the nucleus, several enzymes are known to acetylate histones and
non-histone proteins, using acetyl-CoA from the nuclear-cytosolic pool
as the acetyl group donor. The concentration of acetyl-CoA ﬂuctuates
with the energy state of the cell (Fig. 7), and histone acetyltransferases
appear to bedependent on donor concentration [283,323]. If so, they are
regulated differently than most kinases, which have activities indepen-
dent of the concentration of their cofactor ATP [324,325].
4.2. Effects of acetylation on intermediary metabolic enzymes
Given that most intermediary metabolic enzymes are located in the
mitochondria, there is ample opportunity for regulation of metabolism
through acetylation. In fact, proteins in mitochondria are extensively
acetylated [165,166,243], and enzymes of the major metabolic path-
ways are alsomainly found in acetylated forms. General levels of protein
acetylation in the mitochondria increase with the concentration of Ac-
CoA [326], which is itself dependent on its synthesis rate (reviewed in
[322]). A non-exhaustive list of enzymes involved in intermediate
metabolism which have been found to be modulated, with activity
either increased or decreased, by acetylation, is found in Table 3.
While there are examples of acetylation augmenting the activity of
metabolic enzymes, the majority of the surveyed cases indicate that
acetylation in general inhibits enzymatic activity.
4.3. The mitochondrial acetylation machinery
To our knowledge, only two putative mitochondrial acetyltransfer-
ases have been identiﬁed, which suggests that acetylation in the mito-
chondria is not universally non-enzymatic [327,328] (see Section 4.7).
Mitochondrial acetylation of the pyruvate dehydrogenase complex sub-
unit PDHA1 is catalyzed by the Ac-CoA acetyltransferase ACAT1, and
leads to a loss of its PDH activity. Interestingly, ACAT1 was ﬁrst
identiﬁed as a thiolase catalyzing the reaction of two Ac-CoA into
acetoacetyl-CoA in ketone body metabolism [329]. ACAT1 also acety-
lates pyruvate dehydrogenase phosphatase (PDP), an enzyme which
normally dephosphorylates and activates PDHA1. Deacetylation and ac-
tivation is performed by SIRT3 [189,327]. The ﬁrst suggested mitochon-
drial KAT is GCN5-like 1 (GCN5L1). siRNA-mediated knockdown of
GCN5L1 leads to a marked decrease in mitochondrial acetylation, and
it directly opposes the action of SIRT3 by acetylating components of
the electron transport chain [328].
4.4. The mitochondrial acetylome is inﬂuenced by energy availability
To demonstrate a general interplay between energy use and protein
acetylation, studies have focused on the effect of feeding and fasting on
the acetylome. A study on mouse tissues found that overall mitochon-
drial acetylation in calorie-restrictedmicewas elevated [330], while an-
other group demonstrated that mice on a high-fat diet show increased
mitochondrial protein acetylation [218]. This may be explained by the
fact that while both fasted and fed mitochondria will have high Ac-
CoA concentrations and consequently, concentration-dependent and
non-enzymatic protein acetylation, during fasting, SIRT3 will be upreg-
ulated (Fig. 7) [218,326]. SIRT3 may also be regulated differently in dif-
ferent tissues. In response to fasting and calorie restriction, Sirt3 is
upregulated in liver [218,326], but downregulated in muscle tissue
[331]. Authors of the latter study suggest that the muscle-speciﬁc
downregulation of Sirt3 by fasting is part of a shift away from carbohy-
drate utilization and towards fatty acid oxidation and lactate formation.
SIRT3 may deacetylate and reactivate metabolic enzymes to cope with
the need for increased ATP production through β-oxidation (Fig. 7B).
(see also Section 4.2) Several studies have shown that non-enzymatic
acetylation takes place in the mitochondrial matrix both in vitro and
in vivo, meaning that the mitochondrial acetylation observed may not
need an acetyltransferase to account for itself [169,332].
Fig. 7. Putative impact of energy homeostasis on the acetylome. Proposed model of how the fed (A) and fasted (B) acetylome is inﬂuenced by energy availability to control both gene
transcription and mitochondrial homeostasis. A) In the fed state, high glucose concentrations will lead to high acetyl-CoA concentration in the cytosol and nucleus [323], increased
histone acetylation, and active transcription. In liver mitochondria, high fat availability will give low expression and subsequent low levels of Sirt3, leading to increased acetylation of
mitochondrial proteins, which may or may not be physiologically relevant as a metabolic inhibitory mechanism. B) During fasting, low nuclear-cytosolic acetyl-CoA levels will lead to
low histone acetylation and gene expression. Increased β-oxidation of lipids will lead to elevated levels of acetyl-CoA in the mitochondria, with concomitant nonspeciﬁc and
concentration-dependent protein acetylation in that organelle. However, SIRT3 is also activated in the liver under fasted conditions, and may selectively deacetylate and activate
metabolic enzymes, increasing ATP production.
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Given the presence ofmitochondrial non-enzymatic acetylation (see
Section 4.7) and the low number of identiﬁed mitochondrial acetyl-
transferases,much research on the regulation ofmetabolismby acetyla-
tion has focused on the deacetylases. In mitochondria, SIRT3 is the
major deacetylase. Knocking out Sirt3 leads to hyperacetylation in the
mitochondria, while no such hyperacetylation is seen in Sirt4- or Sirt5-
deﬁcientmice [333]. In vivo knockoutmice have increasedmitochondri-
al acetylation [333,334]. Phenotypically, Sirt3 knockoutmice are healthy
under normal conditions, but show metabolic phenotypes during
fasting, including low ATP levels and inability to cope with coldexposure [326]. Hirschey and colleagues linked this to the increased
acetylation and subsequent inactivation of long-chain acyl-CoA
dehydrogenase (LCAD), a key enzyme in β-oxidation located in the
mitochondria. One study found that Sirt3 KO mice had symptoms of
metabolic syndrome, including insulin insensitivity, obesity, hyperlipid-
emia and steatohepatitis, when placed on a high-fat diet [218]. When
fasted, Sirt3 KO mice fail to deacetylate and activate OTC, and have
altered amino acid proﬁles in the bloodstream [335]. However,
knocking out Sirt3 in mouse liver or skeletal muscle did not lead to
any observable phenotypes [336], suggesting that the Sirt3 metabolic
phenotype is not mediated through the liver or the skeletal muscle.
Authors of the latter study suggested that loss of SIRT3 activity in
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the previous studies. One in vivo proteomics study, conducted onmouse
liver mitochondria, found three distinct classes of mitochondrial acety-
lation sites [337]. These classes are deﬁned by the residues ﬂanking the
acetylated lysine, and by what secondary structural elements they are
part of. Those that have basic residues next to the acetylated lysine,
and in addition are part of alpha helices, are most susceptible to
deacetylation by SIRT3. Neutral or acidic residues next to the acetylated
lysinemake it less available to SIRT3, and as a result these siteswere un-
affected by Sirt3 KO [337,338].
4.6. Feedback control of metabolism and gene regulation by acetylation
Since the acetyl donor, acetyl-CoA, is involved in various catabolic
and anabolic pathways, it has been speculated that the availability of
acetyl-CoA can inﬂuence the extent of protein acetylation. This is the
case for mitochondrial acetylation (see Sections 4.3 and 4.4). However,
chromatin-modifying KATs have also been shown to depend on the
levels of nuclear acetyl-CoA for their activity. ACL is needed for the
increased histone acetylation which occurs when cells are exposed to
serum growth factors. This is catalyzed by GCN5, andmediated through
glucose availability, with increased glucose concentrations giving in-
creases in histone acetylation. Glucose availability was accompanied
by increases in glycolytic gene expression [323]. This supports the idea
that acetyl-CoA levels, which ﬂuctuate based on the energy state of
the cell, can directly inﬂuence the expression of growth genes.
Acetylation of DNA-binding factors can also inﬂuencemetabolism at
the transcriptional level. The peroxisome proliferator-activated
receptor-coactivator 1-alpha (PGC-1-alpha) is an important transcrip-
tion factor regulating gluconeogenesis in fasting and diabetes [339].
Acetylation by GCN5 renders this transcription factor inactive [340],
while it is deacetylated by Sirt1 [341,342]. SIRT6 enhances the activity
of GCN5 towards PGC-1, by deacetylating GCN5 at K549. PGC-1 is then
acetylated, and thus deactivated [343]. Thus, this transcription factor
controlling gluconeogenesis appears to be complementarily regulated
through the opposing actions of two different KDACs and one KAT.
4.7. Non-enzymatic acetylation in the mitochondria and sirtuins as protein
lesion repair enzymes
Because of the high pH and high concentration of Ac-CoA in the mi-
tochondria, it has long been hypothesized that protein acetylation in
mitochondria may occur non-enzymatically [344]. Indeed, enzyme-
independent acetylation has since been demonstrated, and although
two potential mitochondrial acetyltransferases have been identiﬁed,
they cannot account for the observed levels of mitochondrial acetyla-
tion. Studies in S. cerevisiae [332] and in various mouse tissues [345]
have shown that protein acetylation in mitochondria happens to a
very low stoichiometry, in contrast to phosphorylation, a well-
established posttranslational regulatory modiﬁcation, [346] and Nt-
acetylation [39]. This suggests that mitochondrial protein acetylation
is mainly a non-enzymatic lesion caused by the high concentration of
Ac-CoA and high pH in the mitochondria [169]. A function of SIRT3
would then be to repair these lesions [171,345]. However, it cannot be
concluded that all of these acetylation events are protein lesions
which the cell seeks to repair to retain its normal function. High concen-
trations of Ac-CoA could conceivably drive non-enzymatic acetylation
and subsequent protein deactivation, acting as an Ac-CoA sensor and
regulating the rate of Ac-CoA synthesis. In caseswhere lowenergy avail-
ability increases the need for ATP production through β-oxidation, the
concentration-dependent, non-enzymatic protein acetylation of key
metabolic enzymes may be counteracted by site-speciﬁc, SIRT3-
catalyzed deacetylation. As an example, the acetylation of PDHA1 in-
hibits the enzyme, possibly slowing down the rate of Ac-CoA synthesis.
These lysines are highly acetylated in vitro, with stoichiometries of 70%
and 50% for PDHA1 and PDP1, respectively [327]. Although thesemeasurements were not performed on in vivo PDHA1 and PDP1, and
so should be interpreted with some caution, they do suggest a case
where feedback-regulation of Ac-CoA formationmay occur. In addition,
while the impact of a single low-stoichiometry acetylation of a protein
may not inhibit it to a large degree, the effect of several such modiﬁca-
tions on multiple enzymes in a single pathway may, in sum, serve to
feedback-regulate that pathway (see also review [347]).
5. Role of lysine acetylation in diseases
5.1. Aberrant lysine acetylation and its implications in disease
The tight balance between protein acetylation and deacetylation
events play a critical role in the regulation of gene expression and signal
pathways, affecting a range of cellular processes. Dysfunctions in the
balance between KATs and KDACs are therefore associated with a vari-
ety of diseases such as cancer (see Section 5.2), diabetes, cardiac hyper-
trophy, neurodegenerative disorders (see Section 5.4), autoimmunity,
asthma and retroviral pathogenesis [16,317,348–351].
5.1.1. Diabetes
Insulin and glucagon play essential roles in the regulation of the glu-
cose level in blood. Several studies indicate that this aspect of glucose
homeostasis is regulated by epigenetic mechanisms. In general, people
with diabetes have an inability to utilize glucose efﬁciently due to
insulin resistance. In a fed state, insulin promotes glucose uptake to pe-
ripheral tissues, decreases glucose production and stimulates glycogen
synthesis in the liver [352,353]. Once insulin binds to its receptor, the in-
sulin receptor substrate 1 (IRS-1) becomes phosphorylated and acti-
vates PI3K as well as AKT and eventually the glucose transporter 4
(GLUT4), which translocate from intracellular vesicles to the plasma
membranewhere it facilitates glucose uptake [317,354]. Several studies
have shown KDACs to play a regulatory role in this insulin signaling.
HDAC2 can bind to IRS-1 in liver cells, decrease the acetylation and
thereby reduce insulin receptor-mediated tyrosine phosphorylation of
IRS-1. The GLUT4 promoter is governed by the MEF2 binding domain
and Domain I. Noteworthy, different class II HDACs regulate the expres-
sion and activity of GLUT4 and MEF2, in particular HDAC5 and HDAC6
are shown as essential regulators of insulin signaling [355,356]. SIRT1
on the other hand, improves glucose-induced pancreatic insulin secre-
tion and is important in β-cell function. Therefore, it might be a poten-
tial target for diabetes type 2 treatment [357]. Furthermore, HDACs are
also involved in signal transducers and activator of transcription 3
(STAT3)-mediated gluconeogenesis where STAT3 is acetylated by CBP
proteins/p300 and deacetylated by an unknown KDAC(s). This under-
lines the importance of a tightly regulated acetylation/deacetylation
pattern for diseases such as diabetes and obesity [317].
5.1.2. Chronic lung diseases
Chronic lung diseases such as asthma, cystic ﬁbrosis, chronic
obstructive pulmonary disease, interstitial lung disease and acute respi-
ratory distress syndrome are characterized by inﬂammation and coordi-
nate expression of multiple inﬂammatory genes. Pro-inﬂammatory
transcription factors such as NF-κB and activator protein 1 (AP-1) regu-
late many of these inﬂammatory/immune genes. Patients with these
lung diseases typically have an increased KAT expression and increased
acetylation level and a following decreased KDAC activity, favoring in-
creased inﬂammatory gene expression [358]. Typically detected is the
increased acetylation of H3 and H4, in particular H3K18, H4K8 and
H4K12 as a consequence of oxidative stress [351,359].
5.1.3. HIV
Acetylation events are also important for retroviral pathogenesis as
demonstrated with the human immunodeﬁciency virus (HIV-1) [360,
361]. The viral IN protein integrate reverse transcribed HIV-1 DNA
into the cellular genome, and is a substrate for p300-mediated
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terminal domain of IN were identiﬁed acetylation sites. Additionally,
the HIV-1 protein Tat is acetylated at K28 by the p300/CBP-associated
factor (PCAF), while K50 and K51 are substrates for p300/CBP and
GCN5, thus further conﬁrming the essential role of acetylation as a
post-translational modiﬁcation during Tat activation and viral integra-
tion [351,361].
5.1.4. The Rubinstein-Taybi syndrome
The Rubinstein-Taybi syndrome is a rare genetic neurodevelopmental
disorder characterized by postnatal growth deﬁciency, skeletal abnor-
malities, dysmorphic features andmental retardation [362,363]. A certain
level of CBP is essential for normal development as inactivation of one
CBP allele cause this disease [363,364], but the syndrome is also caused
by de novomutations in p300 [365]. The mutations vary from relatively
large deletions of exons which remove the entire gene, to point muta-
tions, translocations or inversions disrupting the gene [366]. Both CBP
and p300 regulate gene expression through their histone acetyltransfer-
ase activity and regulate multiple pathways involved in cell growth,
control, DNA repair, differentiation, apoptosis and tumor suppression
[367]. In 2004, Alarcon and colleagues found chromatin acetylation,
memory and hippocampal long-term potential to be impaired in mice
with only one CBP allele [368]. Studies by Wang et al. demonstrated
that CBP is essential for differentiation of neurons and glial cells in
the embryonic cortex [369]. Furthermore, they found this epigenetic
switch regulated by aPKC ζ-directed phosphorylation of CBP S436.
Typically, mouse models lacking CBP expression had a reduced
acetylation-level of H2B and H2A, however by introducing HDAC
inhibitors these histone acetylation deﬁcits could be reduced [370]. A
range of mutations and aberrations in CBP and p300 genes found
in Rubinstein-Taybi syndrome are summarized [365,370,371].
Interestingly, Rubinstein-Taybi syndrome patients have an increased
predisposition to cancer [372].
5.1.5. Pathogenic mutations in lysine acetyltransferases
Two de novo mutations c.3385C N T (p.R1129*) and c.3070C N T
(p.R1024*) found in the lysine acetyltransferase gene KAT6Awere iden-
tiﬁed in individuals with a dominant autosomal disease and further
highlight lysine acetylation as essential for normal development [373].
The four probands with these nonsense mutations displayed develop-
mental delays, speech delays, microcephaly, craniofacial dysmorphism,
feeding difﬁculties, cardiac defects as well as ocular anomalies. The
KAT6A mutations caused aberrant H3K9 and H3K18 acetylation as
well as altered p53 signaling [373]. KAT6A acetylates K120 and K382
in p53, and both the HAT domain as well as the serine and methionine
rich domain of KAT6A are required for p53 interaction [374]. Another
ﬁve de novo mutations in the C-terminal transactivation domain of
KAT6Awere identiﬁed in six unrelated familymembers with intellectu-
al disability and common phenotypes as already described in the study
of Arboleda and colleagues [375]. These mutations included
c3116_3117 delCT, p.S1039*; c.3830_3831insTT, p.R1278Sfs*17;
c.3879 dupA, p.E1294Rfs*19; c.4108G N T p.E1370*; c.4292 dupT,
p.L1431Ffs*8 in addition to a 0.23 MB microdeletion of the entire read-
ing frame of KAT6A. Further demonstrating the importance of an intact
C-terminal domain is the truncating mutations in KAT6B, a KAT6A
paralogue [375]. These mutations are occurring with high frequency in
genitopatellar syndrome and Ohdo/Say-Barber-Biesecker syndrome,
and further complement previous studies of KAT6A knockout zebraﬁsh
and mice demonstrating similar developmental defects [375–378].
Grave's disease is a typical organ-speciﬁc autoimmune disease and
the most common cause of hyperthyroidism [379]. Also here, a de-
creased H4 acetylation pattern was observed as well as increased
HDAC1 and 2 expression levels [380]. However, no difference was
observed in SIRT1 or the KATs p300 and CBP. As demonstrated by the
different roles and regulations of histone deacetylases, their inhibitors
are promising drug targets for a wide range of diseases includingneurodegenerative and psychiatric disorders, cancer, cardiovascular
dysfunction, autoimmunity and diabetes.
5.2. The impact of lysine acetylation on tumor biology and cancer
The global histone acetylation level in different tissues and cell types
are heterogenic. However, several KDACs show aberrant expression in
different tumor tissues and display a non-redundant function. Metabol-
ic alterations and KDACs deregulation are therefore important hall-
marks in cancer cells [381–384]. Immunohistochemical studies on a
variety of cancer tissues have demonstrated a link between low
cellular levels of histone acetylation and aggressive cancers with poorer
clinical outcome such as decreased survival rate and increased risk of
tumor recurrence [348,385–389]. Lysine acetylation of histone
N-terminal tails is associated with chromatin opening and active
transcription of genes in regions adjacent to the acetylated histones. In
general, most KATs and KDACs may be both oncoproteins and tumor
suppressors, depending on the cellular context. Since the many genes
whose transcription they activate or repress may themselves either
propagate or halt cancer progression, this is not surprising. In other
words, the outcome for cancer progression of histone acetylation is
dependent on whether it happens in the genomic region of a tumor
suppressor or a tumor promoter.
5.2.1. CBP/p300
Small-cell lung cancer is an aggressive lung tumor with poor
prognosis. Extensive global genome analyses revealed inactivating
mutations in the genes of CBP and p300, both important histone
modiﬁers, in small cell lung cancer [390]. The mutations in CBP and
p300were clustered around the HAT domain and at the interface of sub-
strate binding and thus possibly affecting the catalytic activity [390,
391]. Indeed, D1399 (CBP) and D1435 (p300) mutations affected the
acetylation activity in vitro [391–393]. The essential functions of CBP
and p300 are further strengthened by identiﬁcation of a range of other
mutations in different tumors. The p.G1411E mutation in CBP was
found in lung cancer [394] and follicular cancer [395] and p.G1411V
and p.D1435G were found in relapsed acute lymphoblastic leukemia
[396,397]. Furthermore, the p.R386fs alteration and the CBP-RHBDF1
gene fusion results in a truncated protein and inactivation of the enzy-
matic activity [390,398]. The p.G114R, pE1435Y and pS1432P mutation
in CBP, homologous to pG1375R, p.E1399Y and p.S1396P alterations in
p300 all reduced the H3K19 acetylation in mice [399]. Somatic muta-
tions in CBP and p300 genes also affect the response of HDAC inhibition
in malignant B-cell lymphoma. This further demonstrates the implica-
tions of loss-of-acetylation on tumor development as this caused BCL6
overexpression and p53 inactivation [400–402]. Acetylation of p53
leads to its activation, while in contrast acetylation of BCL6 inhibits
this oncoprotein. BCL6 inhibits the transcription of p53 and the p53-
mediated apoptosis occurring in germinal centered B-cells. As such,
DNA strand breaks and somatic mutations occurring in these cells
escape from correction and the surviving cells eventually contribute to
the development of B-cell lymphoma. Acetylation of BCL6 blocks the
recruitment of HDACs to transcription start sites and thereby
HDAC-mediated repression of target genes. The chromosomal loss or
inactivating mutations of CBP and p300 in cancer tissue indicate a
more tumor suppressive role of these proteins.
5.2.2. GCN5
GCN5 is the KAT subunit of the human SAGA complex (reviewed in
[403]). It acetylates both histones and non-histone proteins. Its acetyla-
tion of H3 at K9 and K14 are general markers of active transcription
(reviewed in [404]). The oncoprotein transcription factor Myc recruits
the SAGA complex to chromatin, where it acetylates and activates tran-
scription ofMyc response genes (Fig. 6C) [405,406]. GCN5 acetylates the
Myc protein itself, rendering it more stable than its unacetylated coun-
terpart [407]. Disruption of Myc leads to large-scale hypoacetylation.
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conditional mouse Gcn5 knockout in neural stem cells led to large-scale
gene expression changes which partially overlapped with those seen in
Myc knockouts [409]. Thus, Myc and GCN5 appear to cooperate in a
feed-forward loop of activating transcription. Consistent with these ex-
perimental ﬁndings, GCN5 and the SAGA complex have been implicated
in cancer development. For example, GCN5 was found to be highly
expressed in non-small cell lung cancer. Its expression correlated with
tumor size, and it was recruited by E2F1 to induce histone acetylation
and subsequent activation of E2F1 and the mitotic genes cyclin D1 and
cyclin E1 [410].
5.2.3. PCAF
In contrast to what appears to be a general tumor-promoting role of
GCN5, its paralog, the acetyltransferase PCAF may be a tumor suppres-
sor (see review [404]). PCAF and p300 both acetylate the tumor sup-
pressor p53 in vivo, though at different lysine residues. The acetylation
of p53 increases its DNA binding capacity [411,412]. In fact, acetylation
appears to be essential for p53-mediated growth arrest and apoptosis
[257]. Acetylation is also required for p53-mediated induction of
apoptosis through HDAC-inhibitors [413] and through the microtubule
inhibitor Taxol [414]. The acetylation of p53 byMOF or Tip60 on K120 is
important for its activation of pro-apoptotic genes (reviewed in [415]).
p53 is deacetylated by SIRT1 [416].
5.2.4. MOF
Loss of acetylation at K16 of H4 was found to be present in several
humanneoplasms, implicating it as a hallmark for cancer [386]. This his-
tone modiﬁcation is important for higher order chromatin structure
[233]. The MOF acetyltransferase is very speciﬁc for H4K16 [417], and
appears to be the main acetyltransferase of this site, as Mof knockout
mice lack H4K16 [418]. Mof knockouts show cell cycle arrest, genome
instability and defects in repair of DNA lesions [138].
5.2.5. HDACs
As seen with the KATs, KDACs have mutations or show aberrant ex-
pression in tumors. HDAC1 expression is elevated in gastric cancer and
associatedwith nodal spread, and is as such a prognosticmarker for sur-
vival [419]. However, both elevated HDAC1 and HIF1α expression in
pancreatic cancers were associated with poor prognosis [420]. HDAC1
is implicated in the control of cell proliferation. Knockdown studies in
breast cancer cells and osteosarcoma demonstrate G1 arrest or G2/M
transition arrest and an increasing amount of apoptotic cells [421]. On
the contrary, HDAC1 overexpression led to an increased proliferation
as well as an undifferentiated phenotype in prostate cancer cells [422].
Somatic mutations found in HDAC2 in human epithelial cancers con-
ferred resistance towards anti-proliferative and anti-apoptoticHDAC in-
hibitors [423,424]. Furthermore, several HDAC4mutations were found
in breast and colorectal cancer samples [425]. Similarly, ranges of
othermutations or dysregulated expression levels exist for the different
groups of HDACs and are reviewed in [348,426].
5.2.6. Sirtuins
The different sirtuins are essential for maintenance of the genomic
integrity and reviewed in [318]. SIRT2 acts as a tumor suppressor and
is involved in cell cycle progression, while SIRT3 on the other hand
acts as both a tumor suppressor and promoter. The complexity and
interplay between the sirtuins are further demonstrated by SIRT1, 2, 6
and 7 direct modulation of Myc function [427].
Depending on the tissue and cellular context, SIRT6 may function as
an oncogene or as a tumor suppressor (reviewed in [427]). Normally,
this cytosolic sirtuin will deacetylate H3K9ac [428] and H3K56ac [429,
430], which normally contribute to telomere integrity and help avoid
premature senescence [428]. Some studies ﬁnd that SIRT6 is a tumor
suppressor. For example, Sebastián et al. found that decreased levels
of SIRT6 leads to upregulation of targets of its repressive activity, namelyMyc and HIF1, leading to increased cell division and glycolysis, both
hallmarks of cancer [431]. Other studies have for example found that
SIRT6 increases the expression of cytokines which contribute to
inﬂammation, and to enhance themigratory ability of pancreatic cancer
cells [432].
5.3. The role of sirtuins in aging
The discovery that sirtuin overexpression appears to increase
lifespan in several model animals has led to a great deal of research
into their function and regulation (reviewed in [433]). Initially, yeast
sir2 overexpressionwas discovered to give yeast cells increased lifespan
[434]. Following this, C. elegans with an extra copy of the sir-2.1 gene
was found to have longer lifespan than wild type worm [435]. In D.
melanogaster, increases in dSir2 expression leads to increase in lifespan
in a dosage-dependent manner, nevertheless very high (N5 fold
compared to normal expression) expression results in cytotoxicity and
concomitantly decrease in lifespan [436].
SIRT6 has spectacular effects when misexpressed. Sirt6 knockout
mice develop normally, but are small and have reduced amounts of
body fat, lymphopenia and osteopenia. They die before one month of
age from low blood glucose [437]. Sirt6 KO cells show telomere defects
and early senescence [428]. Male mice who overexpress SIRT6, on the
other hand, have increased lifespan [438]. This phenotypewas connect-
ed to a decrease in the levels of circulating insulin-like growth factor 1
(IGF1) through the upregulation of IGF-binding protein 1, which is a
modiﬁer of IGF1 bioavailability [438]. Histone H1 is acetylated at K26,
and deacetylation is catalyzed by SIRT1 [439]. SIRT1-mediated
deacetylation of this residue and transcriptional repression was found
to be lost in cells subjected to oxidative stress. Mice which overexpress
SIRT1 or are treated with a sirtuin activator (resveratrol) have de-
creased mortality from radiation-induced cancer, suggesting that this
protein may offer protection from the effects of DNA damage [440]. In-
creased ROS formation promotes lifespan and metabolic health reac-
tions. Earlier studies indicate that nicotinamide (NAM) and its
metabolite, 1-methylnicotinamide methyltransferase (MNA), promote
this formation by inhibiting complex I in the respiratory chain. Interest-
ingly, sirtuins contribute to these lifespan extensions in C. elegans by
increasing the amount of the MNA precursor NAM through a
deacetylation-independent mechanism, promoting the metabolic
formation of the pro-oxidative substrate MNA. Instead, this sirtuin-
mediated lifespan extension depends on methylation of NAM and pro-
vides a new mechanistic role for sirtuins beyond the classical histone
deacetylation events [441].
5.4. Lysine acetylation in neurodegenerative disease
One of the hallmarks of Alzheimer's disease is tau protein
hyperphosphorylation. Hyperphosphorylated tau aggregates into ﬁ-
brils. This ﬁbril formation and subsequent formation of insoluble
plaques is a major factor in the etiology of Alzheimer's and related dis-
eases, termed tauopathies [442]. Tau is also acetylated by p300, and
deacetylated by SIRT1 [443]. SIRT1 levels correlate negatively with tau
ﬁbril accumulation and with Alzheimer's symptom duration [444].
Compared to its non-acetylated counterpart, acetylated tau is prone to
accumulate. When tau is acetylated, lysines which could otherwise
become ubiquitinated are blocked. Due to abrogation of this targeting
for proteosomal degradation, tau accumulates and contributes to
Alzheimer's progression [443]. When tau becomes acetylated it does
not promotemicrotubule assembly, which is part of its normal function,
and thus is prone to aggregate. This demonstrates how the mutual ex-
clusion of two different lysine modiﬁcations can determine the fate of
a protein, with physiologically crucial consequences. Acetylation of tau
K280 was found in several human tauopathies [445]. A further study
implicated K174 acetylation as a pathogenic event, rendering tau insol-
uble and more prone to aggregation. However, this speciﬁc acetylation
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quent degradation, as the same pathogenic changes were seen with a
K174Qmutant, which mimics acetylation [446]. Additionally, increased
expression of HDAC2 and decreased histone acetylation are associated
with the cognitive decline typical seen in Alzheimer's [447]. As
reviewed in [279], HDAC2 binding to the promoters of genes involved
in synaptic plasticity and learning such as synaptophysin and BDNF re-
sults in reduced expression as well as reduced histone acetylation. A
negative-feedback loop on memory-sustained gene expression has
been proposed. Interestingly, differentHDAC inhibitors showpromising
results as treatments for age-related cognitive impairment [279].
6. Future perspectives
6.1. The manifold physiological roles of Nt-acetylation decipher hardly
Whydoes the cell Nt-acetylate proteins? Although severalmolecular
consequences for Nt-acetylation have been described, an overall con-
cept for its physiological role remains elusive. Especially the fact that
around 80–90% of the human proteome is Nt-acetylated co- or post-
translationally, makes the interpretation of data and the conclusion of
a general rule difﬁcult. Additionally, the different roles of NAT com-
plexes in the tumorigenic process, and their involvement for different
cancer tissues complicate the answer to the abovementioned question
even more. Varshavsky and colleagues give a plausible explanation for
Nt-acetylation as being part of a degradation signal in the N-end rule
pathway, and therefore part of the proteasomal degradation system
[90,448]. Nevertheless, more complexity is introduced by additional
ﬁndings. The ubiquitin ligase Doa10 in yeast targets several proteins
that are Nt-acetylated and non-acetylated [449]. Furthermore,
ubiquitination which occurs at the N-terminus (e.g. catalyzed by the
E2 enzyme Ube2w) can be prevented by Nt-acetylation, thus inhibiting
degradation [450,451]. The exact contribution of Nt-acetylation in pro-
tein degradation will be part of upcoming studies.
Further, high expression levels of different NATs often correlate with
low survival rates and aggressiveness of different types of tumors, while
NAT depletion studies further demonstrate p53-mediated apoptosis as
well as cancer cell sensitization for drug-induced cell death. As the
NATs are essential for cell cycle progression and have several anti-
apoptotic roles in cancer, they are potential therapeutic targets in cancer
therapy. Indeed, NAT-inhibitors are under development with the ulti-
mate goal of utilization in clinical treatment as well as further studying
the cellular roles of NATs [452].
6.2. Do NATs have lysine acetyltransferase activity?
Is Naa10 a KAT in vivo? Several reports indicate that Naa10 is able to
acetylate lysines, sometimes with physiologically important conse-
quences. However, a recent follow-up study of these proteins as Naa10
substrates found that their acetylation was Naa10-independent, and
that increasing concentrations of acetyl-CoA was sufﬁcient to acetylate
these proteins [453]. The structure of Naa10 also has an extended loop
over the active site, which blocks lysines in sidechains from entering it.
This same loop is found in all the solved NAT structures currently avail-
able; it is not found in the known KATs. This doesn't necessarily close
the book on Naa10 as a KAT, but researchers studying it should keep it
in mind.
6.3. New methods and approaches will shed light on lysine acetylation
pathways
By the recently extensive use ofmass spectrometry-based global anal-
ysis of lysine acetylation, many acetylation sites in proteins have been
identiﬁed, nevertheless not all acetylation events are assigned to speciﬁc
functional roles. The effects on metabolic enzymes have been investigat-
ed intensively, but neither the dynamic regulation nor the stoichiometryof acetylation events in these non-histone proteins is completely solved.
In addition, several studies described important crosstalks between acet-
ylation and various PTMs (including phosphorylation and methylation),
such as it was shown for the histones H3 and H4 [272]. These crosstalks
demonstrate that epigenetic gene regulation by PTMs is a very complex
but ﬁne-tuned mechanism. The further characterization of these mutual
PTM interplays and their functional consequences as well as the charac-
terization of lysine acetyltransferase pathways and the required quantita-
tive analysis of lysine acetylation events are and will be under constant
further investigations, especially by the development of new and more
optimized MS-based approaches [454].
6.4. Is lysine acetylation ofmitochondrial proteins enzymatically regulated?
It appears that most mitochondrial and cytosolic intermediary met-
abolic enzymes are acetylated, and that acetylation generally impairs
the catalytic activity of the acetylated enzymes, although in some
cases the opposite is true. Two likely mitochondrial acetyltransferases
have been discovered, but it is probable that a large proportion of mito-
chondrial acetylation events are non-enzymatic, and that some should
be regarded as a stress factor detrimental to protein function, rather
than a regulatory mechanism. A function of SIRT3, the main mitochon-
drial deacetylase, would then be to repair these lesions [345]. Further
research should explain how acetylation affects the relationship be-
tween metabolic regulation and carbon stress. The discovery of any
novel mitochondrial acetyltransferases would be a major step forward
in this respect. Clarifying the in vivo substrates of the two identiﬁed mi-
tochondrial acetyltransferases should give clues about what metabolic
processes are impacted by acetylation, in or out of a feedback loop.
Whether N-terminal acetylation is governed by similar metabolic feed-
back loops to lysine acetylation is an open question.
7. Concluding remarks
While lysine acetylationdeﬁnitely has gained and earned its position
in the spotlight, Nt-acetylation is still lurking in the shadows. It is not a
numbers game since Nt-acetylation modiﬁes at least as many proteins
in a eukaryotic cell as lysine acetylation does. The key word is biological
impact. Reversible lysine acetylation acts as an essential regulatory
modiﬁcation in multiple cellular pathways. In contrast, the importance
of the more static Nt-acetylation has only been shown in a couple of bi-
ological contexts. However, these ﬁelds are moving fast. While nothing
may undermine the strong position of lysine acetylation, Nt-acetylation
is trying to close the gap.
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